

# The history and advances in cancer immunotherapy: understanding tumor-infiltrating immune cells and their therapeutic implications

Cellular and Molecular Immunology

17, 807-821

DOI: 10.1038/s41423-020-0488-6

Citation Report

#	ARTICLE	IF	CITATIONS
1	Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer. International Immunopharmacology, 2020, 89, 107078.	3.8	25
2	A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-Molecule BCG Mimics to Reduce or Prevent COVID-19 Mortality. Pharmaceutical Research, 2020, 37, 212.	3.5	14
3	Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers, 2020, 12, 3380.	3.7	71
4	Alteration in Gene Pair Correlations in Tryptophan Metabolism as a Hallmark in Cancer Diagnosis. International Journal of Tryptophan Research, 2020, 13, 117864692097701.	2.3	5
5	Immunological Features of Melanoma: Clinical Implications in the Era of New Therapies. , 2021, , 99-128.		0
6	Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers. , 2021, , 77-126.		1
7	GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer. Oncology Reports, 2021, 45, 997-1010.	2.6	7
8	The screening of immune-related biomarkers for prognosis of lung adenocarcinoma. Bioengineered, 2021, 12, 1273-1285.	3.2	22
9	Overcoming the challenges associated with CD3+ T-cell redirection in cancer. British Journal of Cancer, 2021, 124, 1037-1048.	6.4	42
10	Cytosolic Delivery of Thiolated Neoantigen Nanoâ€Vaccine Combined with Immune Checkpoint Blockade to Boost Antiâ€Cancer T Cell Immunity. Advanced Science, 2021, 8, 2003504.	11.2	34
11	Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab072.	0.7	4
12	Single-Cell Profiling to Explore Immunological Heterogeneity of Tumor Microenvironment in Breast Cancer. Frontiers in Immunology, 2021, 12, 643692.	4.8	24
13	Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Seminars in Cancer Biology, 2022, 78, 78-89.	9.6	16
14	New Insights Into the Cancerâ€Microbiomeâ€Immune Axis: Decrypting a Decade of Discoveries. Frontiers in Immunology, 2021, 12, 622064.	4.8	91
16	Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics. Frontiers in Immunology, 2021, 12, 597651.	4.8	9
17	Decoding the genetic basis of anti-tumor immunity. Immunity, 2021, 54, 199-201.	14.3	4
18	Identification of PSMD7 as a prognostic factor correlated with immune infiltration in head and neck squamous cell carcinoma. Bioscience Reports, 2021, 41, .	2.4	10
19	Remodeling of Stromal Cells and Immune Landscape in Microenvironment During Tumor Progression. Frontiers in Oncology, 2021, 11, 596798.	2.8	21

#	ARTICLE	IF	CITATIONS
20	Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113170.	5.5	32
21	The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery. <i>Cancers</i> , 2021, 13, 1305.	3.7	14
22	Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy. <i>Cancers</i> , 2021, 13, 1481.	3.7	20
23	The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 628332.	3.5	73
24	Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2337-2356.	6.7	51
26	Artificial intelligence prediction model for overall survival of clear cell renal cell carcinoma based on a 21-gene molecular prognostic score system. <i>Aging</i> , 2021, 13, 7361-7381.	3.1	7
27	Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment. <i>Annual Review of Immunology</i> , 2021, 39, 583-609.	21.8	153
28	Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4802.	4.1	6
29	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. <i>Molecules</i> , 2021, 26, 2201.	3.8	23
30	Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model. <i>Pharmaceutics</i> , 2021, 13, 547.	4.5	10
31	Aryl Urea Based Scaffolds for Multitarget Drug Discovery in Anticancer Immunotherapies. <i>Pharmaceutics</i> , 2021, 14, 337.	3.8	8
32	Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices. <i>Journal of Pharmaceutical Investigation</i> , 2021, 51, 399-412.	5.3	26
33	Therapeutic potential of interleukin-15 in cancer (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 675.	1.8	28
34	Biomechanical Properties of Cancer Cells. <i>Cells</i> , 2021, 10, 887.	4.1	30
35	Identification of Hub Genes and Their Correlation With Immune Infiltration Cells in Hepatocellular Carcinoma Based on GEO and TCGA Databases. <i>Frontiers in Genetics</i> , 2021, 12, 647353.	2.3	27
36	Cancer neoantigens as potential targets for immunotherapy. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 51-60.	3.3	24
37	Comprehensive analysis of clinical prognosis and molecular immune characterization of tropomyosin 4 in pancreatic cancer. <i>Investigational New Drugs</i> , 2021, 39, 1469-1483.	2.6	10
38	The Orphan Nuclear Receptor Gene NROB2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 691199.	2.8	5

#	ARTICLE	IF	CITATIONS
39	Immunological analysis of the murine anti-CD3 $\epsilon$ -induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies. <i>European Journal of Immunology</i> , 2021, 51, 2074-2085.	2.9	11
40	Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 696716.	2.8	15
42	Tristetraprolin, a Potential Safeguard Against Carcinoma: Role in the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 632189.	2.8	6
43	Programmed death ligand-2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2021, 53, 287-293.	0.7	3
44	Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 265.	2.7	39
45	B Cell Orchestration of Anti-tumor Immune Responses: A Matter of Cell Localization and Communication. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 678127.	3.7	63
46	Nanomedicine-mediated optimization of immunotherapeutic approaches in cervical cancer. <i>Nanomedicine</i> , 2021, 16, 1311-1328.	3.3	10
47	A Novel Risk Model Based on Lipid Metabolism-Associated Genes Predicts Prognosis and Indicates Immune Microenvironment in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 691676.	3.7	14
48	The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6560.	4.1	88
49	Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells. <i>Cancers</i> , 2021, 13, 3298.	3.7	5
50	Monitoring Immunotherapy With Optical Molecular Imaging. <i>ChemMedChem</i> , 2021, 16, 2547-2557.	3.2	6
51	Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer. <i>Aging</i> , 2021, 13, 16287-16315.	3.1	19
52	Pan-Cancer Analysis of the Prognostic and Immunological Role of HSF1: A Potential Target for Survival and Immunotherapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-21.	4.0	34
53	PER1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Ovarian Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 697471.	2.3	7
54	ceRNA network development and tumor-infiltrating immune cell analysis in hepatocellular carcinoma. <i>Medical Oncology</i> , 2021, 38, 85.	2.5	9
55	Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypes. <i>Npj Genomic Medicine</i> , 2021, 6, 52.	3.8	15
56	KCNN4 is a potential prognostic marker and critical factor affecting the immune status of the tumor microenvironment in kidney renal clear cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 2454-2470.	1.4	15
57	Hepcidin Downregulation Correlates With Disease Aggressiveness And Immune Infiltration in Liver Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 714756.	2.8	16

#	ARTICLE	IF	CITATIONS
58	Octogenariansâ€™ Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival. <i>Cancers</i> , 2021, 13, 2933.	3.7	4
59	Biomimetic sonodynamic therapy-nanovaccine integration platform potentiates Anti-PD-1 therapy in hypoxic tumors. <i>Nano Today</i> , 2021, 38, 101195.	11.9	65
60	Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling. <i>Clinical Cancer Research</i> , 2021, 27, 4781-4793.	7.0	14
61	Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 688298.	3.5	12
62	Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour. <i>Nature Communications</i> , 2021, 12, 4405.	12.8	19
63	Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2083-2100.	10.5	40
64	A Comprehensive Pan-Cancer Analysis of RBM8A Based on Data Mining. <i>Journal of Oncology</i> , 2021, 2021, 1-16.	1.3	2
65	HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity. <i>Cancers</i> , 2021, 13, 3575.	3.7	35
66	GARP Correlates With Tumor-Infiltrating T-Cells and Predicts the Outcome of Gastric Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 660397.	4.8	13
67	Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. <i>Cellular and Molecular Immunology</i> , 2022, 19, 33-45.	10.5	47
69	Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer. <i>Aging</i> , 2021, 13, 20438-20467.	3.1	21
70	CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies. , 2021, 9, e002741.		18
71	Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 696912.	2.3	5
72	A Single-Chain Variable Fragment Antibody/Chemokine Fusion Protein Targeting Human Endoglin to Enhance the Anti-Tumor Activity of Cytokine-Induced Killer Cells. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 1574-1583.	1.1	4
73	Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 312.	17.1	50
74	Early phago-/endosomal escape of platinum drugs via ROS-responsive micelles for dual cancer chemo/immunotherapy. <i>Biomaterials</i> , 2021, 276, 121012.	11.4	21
75	Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery. <i>Frontiers in Medicine</i> , 2021, 8, 747333.	2.6	84
76	The Clinical Significance of Mesenteric Lymphocytes in Human Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 685577.	2.8	3

#	ARTICLE	IF	CITATIONS
77	NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. <i>Cancers</i> , 2021, 13, 4543.	3.7	14
78	Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. <i>Biomaterials</i> , 2021, 276, 121018.	11.4	54
79	A Human Pan-Cancer System Analysis of Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 3 (PLOD3). <i>International Journal of Molecular Sciences</i> , 2021, 22, 9903.	4.1	6
80	Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 166-179.	4.4	17
81	Therapeutic cancer vaccines revamping: technology advancements and pitfalls. <i>Annals of Oncology</i> , 2021, 32, 1537-1551.	1.2	36
82	CD8+ T cells from experimental in situ breast carcinoma interfere with bone homeostasis. <i>Bone</i> , 2021, 150, 116014.	2.9	9
83	Identification of an Immune-Related Long Noncoding RNA Pairs Model to Predict Survival and Immune Features in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 726716.	3.7	6
84	Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112105.	5.6	6
85	A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine. <i>Cancer Letters</i> , 2021, 522, 184-197.	7.2	17
86	Targeting Tumor Microenvironment-associated Immune Cells with Nanoparticles-based Strategies. <i>Pharmacophore</i> , 2021, 12, 1-10.	1.2	3
87	The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules. <i>Cells</i> , 2021, 10, 228.	4.1	18
88	Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1172-1185.	10.5	55
89	Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. <i>Life</i> , 2021, 11, 105.	2.4	22
90	Radiotherapy and the immune system: More than just immune suppression. <i>Stem Cells</i> , 2021, 39, 1155-1165.	3.2	61
91	Trial watch: intratumoral immunotherapy. <i>Oncolimmunology</i> , 2021, 10, 1984677.	4.6	31
92	CKS2 Overexpression Correlates with Prognosis and Immune Cell Infiltration in Lung Adenocarcinoma: A Comprehensive Study based on Bioinformatics and Experiments. <i>Journal of Cancer</i> , 2021, 12, 6964-6978.	2.5	8
93	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. <i>Frontiers in Immunology</i> , 2021, 12, 765101.	4.8	63
94	Supplementation with Serum-Derived Extracellular Vesicles Reinforces Antitumor Immunity Induced by Cryo-Thermal Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11021.	4.1	2

#	ARTICLE	IF	CITATIONS
95	Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma. <i>Aging</i> , 2021, 13, 23036-23071.	3.1	3
96	Toll-like receptor 3 is a potential prognosis marker and associated with immune infiltration in stomach adenocarcinoma. <i>Cancer Biomarkers</i> , 2022, 34, 77-93.	1.7	3
98	Identification of Three Core Secretome Genes Associated with Immune Infiltration in High Tumor Mutation Burden Across 14 Major Solid Tumors. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6755-6767.	1.8	2
99	Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers. <i>Cancer Cell International</i> , 2021, 21, 566.	4.1	16
100	MC1R Is a Prognostic Marker and Its Expression Is Correlated with MSI in Colorectal Cancer. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1529-1547.	2.4	5
101	The Prognostic and Immunological Value of Guanylate-Binding Proteins in Lower-Grade Glioma: Potential Markers or Not?. <i>Frontiers in Genetics</i> , 2021, 12, 651348.	2.3	1
102	Identifying the hub genes in non-small cell lung cancer by integrated bioinformatics methods and analyzing the prognostic values. <i>Pathology Research and Practice</i> , 2021, 228, 153654.	2.3	1
103	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives. <i>Cells</i> , 2021, 10, 2845.	4.1	6
104	Impact of anesthetics on oncogenic signaling network: a review on propofol and isoflurane. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 49-71.	1.9	5
105	Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures. <i>Frontiers in Oncology</i> , 2021, 11, 761901.	2.8	11
106	Influence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy. <i>Pharmacological Research</i> , 2021, 174, 105966.	7.1	22
107	Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis. <i>Frontiers in Genetics</i> , 2021, 12, 764245.	2.3	7
108	The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens. <i>Immuno-Oncology Technology</i> , 2021, 11, 100043.	0.3	9
109	PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors. <i>Clinical and Translational Oncology</i> , 2022, 24, 586-596.	2.4	1
110	Proteomics as a Complementary Technique to Characterize Bladder Cancer. <i>Cancers</i> , 2021, 13, 5537.	3.7	4
111	The Upregulation of PLXDC2 Correlates with Immune Microenvironment Characteristics and Predicts Prognosis in Gastric Cancer. <i>Disease Markers</i> , 2021, 2021, 1-18.	1.3	3
112	Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 758288.	4.8	13
113	Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. <i>Ecanermedalscience</i> , 2021, 15, 1314.	1.1	1

#	ARTICLE	IF	CITATIONS
114	Immunotherapy in microsatellite instability metastatic colorectal cancer: Current status and future perspectives. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 511-522.	0.3	5
115	Immunotherapy: The future of cancer treatment. <i>Journal of Oral and Maxillofacial Pathology</i> , 2021, 25, 371.	0.6	0
116	T Lymphocyte-Captured DNA Network for Localized Immunotherapy. <i>Journal of the American Chemical Society</i> , 2021, 143, 19330-19340.	13.7	51
117	Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, e2103836.	11.2	142
118	TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in Leiomyosarcoma. <i>Molecules and Cells</i> , 2021, 44, 784-794.	2.6	4
119	Nanotherapeutics for immune network modulation in tumor microenvironments. <i>Seminars in Cancer Biology</i> , 2022, 86, 1066-1087.	9.6	3
120	Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 787864.	2.8	11
121	Kidney Cancer and Chronic Kidney Disease: Too Close for Comfort. <i>Biomedicines</i> , 2021, 9, 1761.	3.2	7
122	Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 782852.	4.8	19
123	Impact of immune cells on the hallmarks of cancer: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103541.	4.4	27
125	Novel omics technology driving translational research in precision oncology. <i>Advances in Genetics</i> , 2021, 108, 81-145.	1.8	3
126	Applications of CRISPR-Cas System in Tumor Biology. <i>Oncologie</i> , 2021, 23, 463-492.	0.7	1
127	Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 812713.	4.8	3
128	Biomarker-driven immunotherapy for precision medicine in prostate cancer. <i>Personalized Medicine</i> , 2022, 19, 51-66.	1.5	1
129	The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112588.	5.6	14
130	Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 194-204.	4.4	7
131	Recent advances in clinical trials targeting the kynurenine pathway. , 2022, 236, 108055.		23
132	Chordin-like 1 is a novel prognostic biomarker and correlative with immune cell infiltration in lung adenocarcinoma. <i>Aging</i> , 2022, 14, 389-409.	3.1	9



#	ARTICLE	IF	CITATIONS
133	Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2185-2195.	4.2	14
134	Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	1.3	1
135	Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials. <i>Viruses</i> , 2022, 14, 239.	3.3	18
136	ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24228.	2.1	11
137	Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 73-89.	6.7	13
138	A 25 Gene Panel Predicting the Benefits of Immunotherapy in Head and Neck Squamous Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
139	Spatial omics: Navigating to the golden era of cancer research. <i>Clinical and Translational Medicine</i> , 2022, 12, e696.	4.0	53
140	Systematic analysis of the role of SLC52A2 in multiple human cancers. <i>Cancer Cell International</i> , 2022, 22, 8.	4.1	7
141	Directing hypoxic tumor microenvironment and HIF to illuminate cancer immunotherapy's existing prospects and challenges in drug targets. <i>Current Drug Targets</i> , 2022, 23, .	2.1	2
142	Tumor-Infiltrating CD4+ Central Memory T Cells Correlated with Favorable Prognosis in Oral Squamous Cell Carcinoma. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 141-152.	3.5	9
143	Novel Mouse Models for Cancer Immunology. <i>Annual Review of Cancer Biology</i> , 2022, 6, 269-291.	4.5	9
144	Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker. <i>Phenomics</i> , 2022, 2, 33.	2.9	5
145	Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 823287.	2.8	4
146	Pan-Cancer Analysis Reveals the Multidimensional Expression and Prognostic and Immunologic Roles of VSTM2L in Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 792154.	3.5	3
147	Comprehensive analysis of PTEN-related ceRNA network revealing the key pathways WDFY3-CAS2-miR-21a-5p/miR-221a-3p/miR-222a-3p-TIMP3 as potential biomarker in tumorigenesis and prognosis of kidney renal clear cell carcinoma. <i>Molecular Carcinogenesis</i> , 2022, 61, 508-523.		7
148	Recent advance in nanomaterials for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 435, 134145.	12.7	16
149	Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report. <i>Current Oncology</i> , 2021, 28, 5401-5407.	2.2	5
150	In vitro assessment of stearyl triphenyl phosphonium toxicity in drug-resistant tumor cells. <i>4open</i> , 2022, 5, 6.	0.4	1

#	ARTICLE	IF	CITATIONS
151	Immunogenetic mechanisms in the treatment of cancer. , 2022, , 321-338.		0
152	Pan-Cancer Analysis of Histone Methyltransferase KMT2D with Potential Implications for Prognosis and Immunotherapy in Human Cancer. Combinatorial Chemistry and High Throughput Screening, 2023, 26, 83-92.	1.1	5
153	Shock Waves Enhance Expression of Glycosphingolipid Tumor Antigen on Renal Cell Carcinoma: Dynamics of Physically Unmasking Hidden Intracellular Markers Independent of Gene-Signaling Pathways. Biomedicines, 2022, 10, 545.	3.2	0
154	An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets. Life, 2022, 12, 323.	2.4	4
155	Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. Cancers, 2022, 14, 1216.	3.7	12
156	Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches. , 2022, 10, e003928.		10
157	One stone, many birds: Recent advances in functional nanogels for cancer nanotheranostics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1791.	6.1	12
158	Upregulation of IGF2BP2 Promotes Oral Squamous Cell Carcinoma Progression That Is Related to Cell Proliferation, Metastasis and Tumor-Infiltrating Immune Cells. Frontiers in Oncology, 2022, 12, 809589.	2.8	7
159	The Prognostic Value and Immune Infiltration of USP10 in Pan-Cancer: A Potential Therapeutic Target. Frontiers in Oncology, 2022, 12, 829705.	2.8	4
160	Irradiation immunity interactions. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 519-535.	1.8	2
161	Advances in High Throughput Proteomics Profiling in Establishing Potential Biomarkers for Gastrointestinal Cancer. Cells, 2022, 11, 973.	4.1	9
162	The Development of Chiral Nanoparticles to Target NK Cells and CD8 <sup>+</sup> T Cells for Cancer Immunotherapy. Advanced Materials, 2022, 34, e2109354.	21.0	41
163	What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis. Frontiers in Immunology, 2022, 13, 764643.	4.8	3
164	Probing immune infiltration dynamics in cancer by inÂvivo imaging. Current Opinion in Chemical Biology, 2022, 67, 102117.	6.1	8
165	Functional antigen processing and presentation mechanism as a prerequisite factor of response to treatment with dendritic cell vaccines and anti-PD-1 in preclinical murine LLC1 and GL261 tumor models. Cancer Immunology, Immunotherapy, 2022, 71, 2691-2700.	4.2	5
166	Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Scientific Reports, 2022, 12, 5518.	3.3	5
167	Immunotherapy for head and neck cancer: Present and future. Critical Reviews in Oncology/Hematology, 2022, 174, 103679.	4.4	45
168	Development and Validation of Novel Prognostic Models for Immune-Related Genes in Osteosarcoma. Frontiers in Molecular Biosciences, 2022, 9, 828886.	3.5	7

#	ARTICLE	IF	CITATIONS
169	Comprehensive molecular analysis of a four-pyroptosis-gene signature with prognosis and immune landscape in lung adenocarcinoma. <i>Genomics</i> , 2022, 114, 110355.	2.9	4
170	Virus-like particles: a self-assembled toolbox for cancer therapy. <i>Materials Today Chemistry</i> , 2022, 24, 100808.	3.5	7
171	Mitosis-related gene CENP-U as a potential biomarker in malignancy. <i>Annals of Translational Medicine</i> , 2021, 9, 1744-1744.	1.7	5
172	Gold-Polymer Nanocomposites for Future Therapeutic and Tissue Engineering Applications. <i>Pharmaceutics</i> , 2022, 14, 70.	4.5	23
173	Immunotherapy for cancer: effects of iron oxide nanoparticles on polarization of tumor-associated macrophages. <i>Nanomedicine</i> , 2021, 16, 2633-2650.	3.3	27
174	High Mast Cell Density Predicts a Favorable Prognosis in Patients with Pancreatic Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2022, 112, 845-855.	2.5	7
175	Characterization of m6A RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 782551.	4.8	7
177	Immunologic Gene Sets Reveal Features of the Tumor Immune Microenvironment and Predict Prognosis and Immunotherapy Response: A Pan-Cancer Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 858246.	4.8	1
178	Improving ovarian cancer treatment decision using a novel risk predictive tool. <i>Aging</i> , 2022, 14, 3464-3483.	3.1	4
179	Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse. <i>Heredity</i> , 2022, 129, 64-74.	2.6	4
180	Immunotherapy: The future of cancer treatment. <i>Journal of Oral and Maxillofacial Pathology</i> , 2021, 25, 371.	0.6	10
181	Photodynamic therapy of melanoma with new, structurally similar, NIR-absorbing ruthenium (II) complexes promotes tumor growth control via distinct hallmarks of immunogenic cell death.. <i>American Journal of Cancer Research</i> , 2022, 12, 210-228.	1.4	0
182	Development of Cancer Immunotherapies. <i>Cancer Treatment and Research</i> , 2022, 183, 1-48.	0.5	4
183	Functional deficiency of succinate dehydrogenase promotes tumorigenesis and development of clear cell renal cell carcinoma through weakening of ferroptosis. <i>Bioengineered</i> , 2022, 13, 11187-11207.	3.2	15
184	A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma. <i>Precision Clinical Medicine</i> , 2022, 5, .	3.3	3
185	What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 561-563.	2.4	6
186	The Landscape of the Tumor-Infiltrating Immune Cell and Prognostic Nomogram in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2022, 13, .	2.3	4
187	Disrupting Mechanisms that Regulate Genomic Repeat Elements to Combat Cancer and Drug Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	3.7	5

#	ARTICLE	IF	CITATIONS
188	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. <i>Cancers</i> , 2022, 14, 2408.	3.7	15
189	FLASH with carbon ions: Tumor control, normal tissue sparing, and distal metastasis in a mouse osteosarcoma model. <i>Radiotherapy and Oncology</i> , 2022, 175, 185-190.	0.6	36
190	Recentring neuroscience on behavior: The interface between brain and environment is a privileged level of control of neural activity. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 138, 104678.	6.1	10
191	Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	3.7	35
192	Identification of the circRNA-miRNA-mRNA Prognostic Regulatory Network in Lung Adenocarcinoma. <i>Genes</i> , 2022, 13, 885.	2.4	4
193	High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation. <i>Cancer Immunology Research</i> , 2022, 10, 844-855.	3.4	4
194	Deconvolution of malignant pleural effusions immune landscape unravels a novel macrophage signature associated with worse clinical outcome in lung adenocarcinoma patients. , 2022, 10, e004239.		6
195	Hypercalcemia and Granulomatous-Like Lesions in a Patient with Melanoma after Treatment with Immunotherapy: Case Report. <i>Case Reports in Clinical Medicine</i> , 2022, 11, 188-193.	0.2	0
196	Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-16.	2.2	0
197	PTBP1 as a Promising Predictor of Poor Prognosis by Regulating Cell Proliferation, Immunosuppression, and Drug Sensitivity in SARC. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-26.	4.0	9
198	Harnessing chitosan and poly-( $\beta$ -glutamic acid)-based biomaterials towards cancer immunotherapy. <i>Materials Today Advances</i> , 2022, 15, 100252.	5.2	5
199	A Novel Metabolic-Immune Related Signature Predicts Prognosis and Immunotherapy Response in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
200	The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma. <i>International Journal of Biological Markers</i> , 2022, 37, 322-327.	1.8	5
201	Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
202	Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
203	Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. <i>Advanced Science</i> , 2022, 9, .	11.2	140
204	Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114357.	13.7	20
206	POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer. <i>Aging</i> , 2022, 14, 5195-5210.	3.1	2

#	ARTICLE	IF	CITATIONS
207	Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy. <i>Medicine (United States)</i> , 2022, 101, e29336.	1.0	0
208	Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	9.1	19
209	The Role of Preoperative Neutrophil, Platelet, and Monocyte to Lymphocyte Ratios as Independent Prognostic Factors for Patient Survival in WHO 2021 Glioblastoma: A Single-Center Retrospective Study. <i>Cureus</i> , 2022, , .	0.5	3
210	Identifying the Potential Roles of PBX4 in Human Cancers Based on Integrative Analysis. <i>Biomolecules</i> , 2022, 12, 822.	4.0	3
211	A New Functional Screening Platform Identifies Colistin Sulfate as an Enhancer of Natural Killer Cell Cytotoxicity. <i>Cancers</i> , 2022, 14, 2832.	3.7	0
212	Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer. <i>Cancers</i> , 2022, 14, 2938.	3.7	6
213	CLEC1B is a Promising Prognostic Biomarker and Correlated with Immune Infiltration in Hepatocellular Carcinoma. <i>International Journal of General Medicine</i> , 0, Volume 15, 5661-5672.	1.8	3
214	Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	1
215	Cationic poly(amino acid) surface functionalized manganese nanoparticles for nitric oxide-based immunotherapy and magnetic resonance imaging. <i>Journal of Materials Chemistry B</i> , 2022, 10, 5402-5409.	5.8	7
216	Independent Prognostic Significance and Immunotherapy Response of Overexpressed ECE2 in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
217	Phenylboronic ester-modified polymeric nanoparticles for promoting TRP2 peptide antigen delivery in cancer immunotherapy. <i>Drug Delivery</i> , 2022, 29, 2029-2043.	5.7	5
218	Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	5
219	Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
220	Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. <i>Nature Communications</i> , 2022, 13, .	12.8	45
221	The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	6
222	Roles of exosomal circRNAs in tumour immunity and cancer progression. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	20
223	Identification of Novel Tumor Microenvironment Regulating Factor That Facilitates Tumor Immune Infiltration in Cervical Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
224	Nanobiomaterials to modulate natural killer cell responses for effective cancer immunotherapy. <i>Trends in Biotechnology</i> , 2023, 41, 77-92.	9.3	7

#	ARTICLE	IF	CITATIONS
225	Identification of T cell-related biomarkers for breast cancer based on weighted gene co-expression network analysis. <i>Journal of Chemotherapy</i> , 2023, 35, 298-306.	1.5	2
226	A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	7
227	Identification of Endoplasmic Reticulum Stress-Related Subtypes, Infiltration Analysis of Tumor Microenvironment, and Construction of a Prognostic Model in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 3326.	3.7	2
228	Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes. , 2022, 39, .		7
229	Oncogenetic Function and Prognostic Value of DNA Topoisomerase II Alpha in Human Malignancies: A Pan-Cancer Analysis. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
230	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 3305.	3.7	11
231	Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. <i>Cancer Letters</i> , 2022, 548, 215823.	7.2	21
232	RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
233	EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	6
234	Exploration of the Immunotyping Landscape and Immune Infiltration-Related Prognostic Markers in Ovarian Cancer Patients. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
235	DNA Supramolecular Assembly on Micro/Nanointerfaces for Bioanalysis. <i>Accounts of Chemical Research</i> , 2022, 55, 2043-2054.	15.6	27
236	Tumor necrosis factor alpha and lipopolysaccharides synergistic effects on T-cell immunoglobulin and mucin domain 3 regulation in dendritic cells. <i>Journal of King Saud University - Science</i> , 2022, 34, 102213.	3.5	0
237	Upregulation of MHC-I and downregulation of PD-L1 expression by doxorubicin and deferasirox codelivered liposomal nanoparticles for chemoimmunotherapy of melanoma. <i>International Journal of Pharmaceutics</i> , 2022, 624, 122002.	5.2	5
238	A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma. <i>International Immunopharmacology</i> , 2022, 110, 108846.	3.8	4
239	A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	10
240	Characterization of the immune cell infiltration landscape in myxofibrosarcoma to aid immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
241	AURKA is a prognostic potential therapeutic target in skin cutaneous melanoma modulating the tumor microenvironment, apoptosis, and hypoxia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3089-3107.	2.5	3
242	The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5

#	ARTICLE	IF	CITATIONS
243	Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?. <i>Cancers</i> , 2022, 14, 3575.	3.7	18
244	Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencing. <i>Cancer Biology and Medicine</i> , 0, , 1-18.	3.0	2
245	A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2). <i>Frontiers in Genetics</i> , 0, 13, .	2.3	6
246	Necroptosis-associated long noncoding RNAs can predict prognosis and differentiate between cold and hot tumors in ovarian cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	8
248	New advances in pharmaceutical strategies for sensitizing anti-PD-1 immunotherapy and clinical research. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	6.1	3
249	A synthetic DNA template for fast manufacturing of versatile single epitope mRNA. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 943-954.	5.1	8
250	Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0
251	A novel metabolic-immune related signature predicts prognosis and immunotherapy response in lung adenocarcinoma. <i>Heliyon</i> , 2022, 8, e10164.	3.2	6
252	TNF- $\alpha$ inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
253	Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086.	3.7	3
254	Regulation of dietary polyphenols on cancer cell pyroptosis and the tumor immune microenvironment. <i>Frontiers in Nutrition</i> , 0, 9, .	3.7	6
255	Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	8
256	A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of TOP1MT. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0
257	Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
258	The cross-talk of cancer-associated fibroblasts assist in prognosis and immunotherapy in patients with breast carcinoma. <i>Cancer Gene Therapy</i> , 2022, 29, 2001-2012.	4.6	4
259	Non-negative matrix factorization model-based construction for molecular clustering and prognostic assessment of head and neck squamous carcinoma. <i>Heliyon</i> , 2022, 8, e10100.	3.2	1
260	Nanomaterials: A powerful tool for tumor immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
261	Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	12



#	ARTICLE	IF	CITATIONS
262	Adverse Events Induced by Nivolumab Plus Ipilimumab <i>vs.</i> Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis. Cancer Investigation, 2022, 40, 777-788.	1.3	1
263	A novel signature to predict thyroid cancer prognosis and immune landscape using immune-related LncRNA pairs. BMC Medical Genomics, 2022, 15, .	1.5	1
264	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. Frontiers in Medicine, 0, 9, .	2.6	5
265	Development and validation of a novel fibroblast scoring model for lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	2.8	4
266	Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects. Vaccines, 2022, 10, 1272.	4.4	2
267	NF- $\kappa$ B: blending metabolism, immunity, and inflammation. Trends in Immunology, 2022, 43, 757-775.	6.8	121
268	The evolving role of liquid biopsy in lung cancer. Lung Cancer, 2022, 172, 53-64.	2.0	19
269	Integrating network pharmacology and transcriptomic validation to investigate the efficacy and mechanism of Mufangji decoction preventing lung cancer. Journal of Ethnopharmacology, 2022, 298, 115573.	4.1	5
270	Development of flow cytometry analysis on measuring tumour immune microenvironment (TIME) in mice bearing EMT6 tumour model. Asia-Pacific Journal of Molecular Biology and Biotechnology, 0, , 135-142.	0.1	0
271	A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options. Experimental and Molecular Pathology, 2022, 128, 104832.	2.1	11
272	Single-intraosseous simvastatin injection suppresses cancers via activating CD8+ T cells. Biomedicine and Pharmacotherapy, 2022, 155, 113665.	5.6	5
273	Covalent organic framework nanomedicines: Biocompatibility for advanced nanocarriers and cancer theranostics applications. Bioactive Materials, 2023, 21, 358-380.	15.6	37
274	Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression. Biomaterials Science, 2022, 10, 6077-6115.	5.4	3
275	Radiobioconjugate targeted therapy in cancer, using radiolabeled mediated biological analogs: Desired qualities and selective targeting approach. Biomedical and Biotechnology Research Journal, 2022, 6, 40.	0.6	0
276	Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics, 2022, 12, 6422-6436.	10.0	36
277	Identification of circadian clock genes as regulators of immune infiltration in Hepatocellular Carcinoma. Journal of Cancer, 2022, 13, 3199-3208.	2.5	4
278	Enhanced anticancer efficacy of primed natural killer cells<i>via</i>coacervate-mediated exogenous interleukin-15 delivery. Biomaterials Science, 2022, 10, 5968-5979.	5.4	5
279	Effector Immune Cell Deployment: a revolutionized concept in cancer immunotherapy. Science China Life Sciences, 2023, 66, 1930-1933.	4.9	2



#	ARTICLE	IF	CITATIONS
280	The prognostic value of an immune-related gene signature and infiltrating tumor immune cells based on bioinformatics analysis in primary esophageal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1556-1570.	1.4	0
281	Recent Advances in DNA Vaccines against Lung Cancer: A Mini Review. <i>Vaccines</i> , 2022, 10, 1586.	4.4	4
282	A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review). <i>Oncology Reports</i> , 2022, 48, .	2.6	7
283	Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10617.	4.1	17
284	Recent advances in nano-drug delivery systems for synergistic antitumor immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	3
285	Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0
286	Immune Effect of T Lymphocytes Infiltrated by Tumors on Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	1.3	0
287	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. , 2022, 10, e004884.		15
288	Integrative Analysis of N6-Methyladenosine-Related Enhancer RNAs Identifies Distinct Prognosis and Tumor Immune Micro-Environment Patterns in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4657.	3.7	2
290	Ligands stimulating antitumour immunity as the next G-quadruplex challenge. <i>Molecular Cancer</i> , 2022, 21, .	19.2	18
291	Critical role of guanylate binding protein 5 in tumor immune microenvironment and predictive value of immunotherapy response. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	5
292	Downregulated PRNP Facilitates Cell Proliferation and Invasion and Has Effect on the Immune Regulation in Ovarian Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-11.	2.2	4
293	Bioinformatics-Based Analysis: Noncoding RNA-Mediated COL10A1 Is Associated with Poor Prognosis and Immune Cell Infiltration in Pancreatic Cancer. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-16.	1.9	5
294	Cuproptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of early-stage lung adenocarcinoma patients. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
295	Comprehensive prognostic and immunological analysis of CCT2 in pan-cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
296	High FLT3 expression indicates favorable prognosis and correlates with clinicopathological parameters and immune infiltration in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	6
297	Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy. <i>Pharmaceutics</i> , 2022, 14, 1908.	4.5	7
298	The role of hypoxia-related genes in TACE-refractory hepatocellular carcinoma: Exploration of prognosis, immunological characteristics and drug resistance based on onco-multi-OMICS approach. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8

#	ARTICLE	IF	CITATIONS
299	Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment. <i>Seminars in Immunopathology</i> , 2023, 45, 215-227.	6.1	7
300	Potassium channel-related genes are a novel prognostic signature for the tumor microenvironment of renal clear cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
301	IL-2 Combined with IL-15 Enhanced the Expression of NKG2D Receptor on Patient Autologous NK Cells to Inhibit Wilms's Tumor via MAPK Signaling Pathway. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	1.3	4
302	Melanoma Management: From Epidemiology to Treatment and Latest Advances. <i>Cancers</i> , 2022, 14, 4652.	3.7	32
303	Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
304	Phagocytosis-Regulators-Based Signature to Predict the Prognosis and Chemotherapy Resistance for Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10312.	4.1	2
305	Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications. <i>Pharmaceutics</i> , 2022, 14, 1990.	4.5	17
306	Nanoparticle-Based Therapeutic Strategies for Enhanced Pancreatic Ductal Adenocarcinoma Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 2033.	4.5	5
308	Prognostic value of LECT2 and relevance to immune infiltration in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	5
309	Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
311	Increased Density of Growth Differentiation Factor-15+ Immunoreactive M1/M2 Macrophages in Prostate Cancer of Different Gleason Scores Compared with Benign Prostate Hyperplasia. <i>Cancers</i> , 2022, 14, 4591.	3.7	4
312	Effect of pembrolizumab on T lymphocyte subsets in patients with advanced oral cancer and its therapeutic effect. <i>Medicine (United States)</i> , 2022, 101, e30534.	1.0	1
313	PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer. <i>Journal of Inflammation Research</i> , 0, Volume 15, 5439-5455.	3.5	1
315	Cardiovascular disease and chimeric antigen receptor cellular therapy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
316	Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach. <i>Vaccines</i> , 2022, 10, 1493.	4.4	5
317	Oxadiazole Derivatives as Anticancer and Immunomodulatory Agents: A Systematic Review. <i>Current Medicinal Chemistry</i> , 2023, 30, 3472-3485.	2.4	0
318	Antitumor effect and mechanism of FZD7 polypeptide vaccine. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
319	Knockdown of RAD51AP1 suppressed cell proliferation and invasion in esophageal squamous cell carcinoma. <i>Discover Oncology</i> , 2022, 13, .	2.1	3

#	ARTICLE	IF	CITATIONS
320	Anlotinib Benefits the $\pm$ PDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-18.	4.0	3
321	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
322	Pembrolizumab leading to complete resolution of non-small cell lung cancer and microsatellite instability stable colon adenocarcinoma; two birds one stone. <i>Journal of Case Reports and Images in Oncology</i> , 2022, 8, 20-27.	0.0	0
323	The heterogeneity of oxidized lipids in individual tumor cells reveals NK cell-mediated cytotoxicity by label-free mass cytometry. <i>Analyst</i> , The, 2022, 147, 5754-5763.	3.5	1
324	Smart bio-encapsulation for immunotherapy. , 2022, , 75-90.		0
325	A Redox-responsive Prodrug Nanogel of TLR7/8 Agonist for Improved Cancer Immunotherapy. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2023, 41, 32-39.	3.8	2
326	Supramolecular Coassembled Peptide Hydrogels for Efficient Anticancer Therapy by RNS-Based PDT and Immune Microenvironment Regulation. <i>Macromolecular Bioscience</i> , 2022, 22, .	4.1	3
327	Development of a Hallmark Pathway-Related Gene Signature Associated with Immune Response for Lower Grade Gliomas. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11971.	4.1	14
328	AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model. <i>Molecules</i> , 2022, 27, 6721.	3.8	9
329	Establishment of m7G-related gene pair signature to predict overall survival in colorectal cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	0
330	Cationic lipid potentiated the adjuvanticity of polysaccharide derivative-modified liposome vaccines. <i>Journal of Controlled Release</i> , 2023, 362, 767-776.	9.9	8
331	Novel insight into the role of immunotherapy in gastrointestinal cancer (Review). <i>Molecular and Clinical Oncology</i> , 2022, 17, .	1.0	1
332	Current advances of CRISPR-Cas technology in cell therapy. , 2022, 1, 100067.		10
333	MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer. <i>European Journal of Medical Research</i> , 2022, 27, .	2.2	0
334	PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
335	The Prognostic Significance and Potential Mechanism of Prolyl 3-Hydroxylase 1 in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-24.	1.3	3
336	Graph representation learning in biomedicine and healthcare. <i>Nature Biomedical Engineering</i> , 2022, 6, 1353-1369.	22.5	51
338	Crosstalk between Tumor-Associated Macrophages and MicroRNAs: A Key Role in Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13258.	4.1	5

#	ARTICLE	IF	CITATIONS
339	The Oncogenic and Immunological Roles of Apoptosis Antagonistic Transcription Factors in Human Tumors: A Pan-Cancer Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-16.	4.0	0
340	Managing the TME to improve the efficacy of cancer therapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	36
341	Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer. <i>Journal of Leukocyte Biology</i> , 2022, 112, 1577-1590.	3.3	2
342	Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	6
343	Midostaurin Modulates Tumor Microenvironment and Enhances Efficacy of Anti-PD-1 against Colon Cancer. <i>Cancers</i> , 2022, 14, 4847.	3.7	7
344	Systematic pan-cancer analysis of the nicotinamide n-methyltransferase in human cancer. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
345	The role of cuproptosis-related gene in the classification and prognosis of melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10
346	pH-responsive nanoprodugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer. <i>Acta Biomaterialia</i> , 2022, 154, 497-509.	8.3	15
347	Integrative insights and clinical applications of single-cell sequencing in cancer immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	11
348	Tumor immune checkpoints and their associated inhibitors. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 823-843.	2.8	9
349	Endogenous stimuli-responsive nanoparticles for cancer therapy: From bench to bedside. <i>Pharmacological Research</i> , 2022, 186, 106522.	7.1	13
350	Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade. <i>Cell Reports</i> , 2022, 41, 111553.	6.4	9
351	Single-cell sequencing technologies in bladder cancer research: Applications and challenges. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	4
352	Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier. <i>Cancers</i> , 2022, 14, 4920.	3.7	19
353	Single-cell technologies: From research to application. <i>Innovation(China)</i> , 2022, 3, 100342.	9.1	13
354	Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	2
355	A novel ten-gene prognostic signature for cervical cancer based on CD79B-related immunomodulators. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	1
356	Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5

#	ARTICLE	IF	CITATIONS
357	Reprogramming cell fates towards novel cancer immunotherapies. <i>Current Opinion in Pharmacology</i> , 2022, 67, 102312.	3.5	0
358	Progress in research on the role of amino acid metabolic reprogramming in tumour therapy: A review. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113923.	5.6	7
359	New target DDR1: A “double-edged sword” in solid tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188829.	7.4	5
361	Expression profile and prognostic values of LSM family in skin cutaneous melanoma. <i>BMC Medical Genomics</i> , 2022, 15, .	1.5	3
362	Systematic pan-cancer analysis identifies RALA as a tumor targeting immune therapeutic and prognostic marker. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
363	MiR-125b-5p Targets MTFP1 to Inhibit Cell Proliferation, Migration, and Invasion and Facilitate Cell Apoptosis in Endometrial Carcinoma. <i>Molecular Biotechnology</i> , 2023, 65, 961-969.	2.4	2
365	A SERPINE1-Based Immune Gene Signature Predicts Prognosis and Immunotherapy Response in Gastric Cancer. <i>Pharmaceuticals</i> , 2022, 15, 1401.	3.8	2
366	An engineered hydrogel with low-dose antitumor drugs enhances tumor immunotherapy through tumor interstitial wrap. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	1
367	Comprehensive Analysis Reveals PTK6 as a Prognostic Biomarker Involved in the Immunosuppressive Microenvironment in Breast Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-14.	2.2	1
368	PAIP2 is a potential diagnostic and prognostic biomarker of breast cancer and is associated with immune infiltration. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	2
369	The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy. <i>Seminars in Cancer Biology</i> , 2022, 87, 160-169.	9.6	15
370	HAPLN3 inhibits apoptosis and promotes EMT of clear cell renal cell carcinoma via ERK and Bcl-2 signal pathways. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	4
371	Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
372	A novel costimulatory molecule gene-modified leukemia cell-derived exosome-targeted CD4+ T cell vaccine efficiently enhances anti-leukemia immunity. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
373	Prognosis Risk Model Based on Necroptosis-Related Signature for Bladder Cancer. <i>Genes</i> , 2022, 13, 2120.	2.4	0
374	Research progress in inducing immunogenic cell death of tumor cells. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	9
375	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
376	Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6

#	ARTICLE	IF	CITATIONS
378	Diagnostic, prognostic, and immunological roles of CD177 in cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	3
379	Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 4327-4347.	12.0	78
380	Combination of photosensitizer and immune checkpoint inhibitors for improving the efficacy of tumor immunotherapy. <i>International Journal of Pharmaceutics</i> , 2022, 629, 122384.	5.2	0
381	Exploiting the potential of extracellular vesicles as delivery vehicles for the treatment of melanoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	4
382	Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	1
383	Identification of TGF- $\beta$ 2 signaling-related molecular patterns, construction of a prognostic model, and prediction of immunotherapy response in gastric cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7
384	A versatile metal-organic nanoplatform in combination with CXCR4 antagonist and PD-L1 inhibitor for multimodal synergistic cancer therapy and MRI-guided tumor imaging. <i>Nano Today</i> , 2022, 47, 101689.	11.9	10
385	Case series of head-and-neck adenosquamous carcinoma: Role of histogenetic model in immunotherapy as a future perspective for nonconventional squamous cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 505.	0.9	1
386	Nanocatalysis meets microfluidics: A powerful platform for sensitive bioanalysis. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 158, 116887.	11.4	10
387	Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+ T cell-dependent immune response. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114094.	5.6	2
388	NMI: a potential biomarker for tumor prognosis and immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	2
390	PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10
391	Coagulation- and fibrinolysis-related genes for predicting survival and immunotherapy efficacy in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
393	Laryngeal extra-skeletal Ewing sarcoma treated with DC-CTL immunotherapy: A case report and review of the literature. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
394	Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer. <i>BMC Cancer</i> , 2022, 22, .	2.6	8
395	Pheophorbide A-mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression. <i>Pharmaceutics</i> , 2022, 14, 2513.	4.5	3
397	Prognostic value and immunological role of FOXM1 in human solid tumors. <i>Aging</i> , 2022, 14, 9128-9148.	3.1	4
398	A metabolically engineered bacterium controls autoimmunity and inflammation by remodeling the pro-inflammatory microenvironment. <i>Gut Microbes</i> , 2022, 14, .	9.8	1

#	ARTICLE	IF	CITATIONS
399	Synthesis and immunological evaluation of Mincle ligands-based antitumor vaccines. Chinese Chemical Letters, 2023, 34, 108065.	9.0	0
400	Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors. Cancers, 2022, 14, 6095.	3.7	8
401	A novel cuproptosis-related gene signature predicting overall survival in pediatric neuroblastoma patients. Frontiers in Pediatrics, 0, 10, .	1.9	0
402	Prognosis and immune features of pyroptosis-related RNA patterns in low-grade glioma. Frontiers in Oncology, 0, 12, .	2.8	1
403	Optimization of <scp>CRISPRâ€Cas</scp> system for clinical cancer therapy. Bioengineering and Translational Medicine, 2023, 8, .	7.1	3
405	Prediction of Diagnostic Gene Biomarkers Associated with Immune Infiltration for Basal Cell Carcinoma. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 15, 2657-2673.	1.8	2
406	Screening of an individualized treatment strategy for an advanced gallbladder cancer using patient-derived tumor xenograft and organoid models. Frontiers in Oncology, 0, 12, .	2.8	1
407	Editorial: Induced cell senescence as a therapeutic strategy for cancer treatment. Frontiers in Oncology, 0, 12, .	2.8	0
408	Noninvasive Imaging of Tumor PD-L1 Expression Using [ <sup>99m</sup> Tc]Tc-Labeled KN035 with SPECT/CT. Molecular Pharmaceutics, 2023, 20, 690-700.	4.6	6
410	Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). Oncology Letters, 2022, 25, .	1.8	7
411	Prognosis and pain dissection of novel signatures in kidney renal clear cell carcinoma based on fatty acid metabolism-related genes. Frontiers in Oncology, 0, 12, .	2.8	3
412	PLK4 initiates crosstalk between cell cycle, cell proliferation and macrophages infiltration in gliomas. Frontiers in Oncology, 0, 12, .	2.8	4
413	Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects. , 2023, 40, .		3
414	Flexible Skin Patch Enabled Tumor Hybrid Thermophysical Therapy and Adaptive Antitumor Immune Response. Advanced Healthcare Materials, 2023, 12, .	7.6	7
415	The novel m6A writer METTL5 as prognostic biomarker probably associating with the regulation of immune microenvironment in kidney cancer. Heliyon, 2022, 8, e12078.	3.2	2
416	Integrative analyses of a mitophagy-related gene signature for predicting prognosis in patients with uveal melanoma. Frontiers in Genetics, 0, 13, .	2.3	1
417	Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer. Acta Biomaterialia, 2023, 158, 547-559.	8.3	7
418	Engineering time-controlled immunotherapy. Science, 2022, 378, 1175-1176.	12.6	0



#	ARTICLE	IF	CITATIONS
419	Identification and validation of RNA methylation-related alternative splicing gene signature for low-grade glioma to predict survival and immune landscapes. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	0
420	Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors. Disease Markers, 2022, 2022, 1-20.	1.3	6
421	Encapsulation of Platinum Prodrugs into PC7A Polymeric Nanoparticles Combined with Immune Checkpoint Inhibitors for Therapeutically Enhanced Multimodal Chemotherapy and Immunotherapy by Activation of the STING Pathway. Advanced Science, 2023, 10, .	11.2	25
422	Activation of cancer immunotherapy by nanomedicine. Frontiers in Pharmacology, 0, 13, .	3.5	4
423	mRNA vaccines for cancer immunotherapy. Frontiers in Immunology, 0, 13, .	4.8	33
424	Cancer treatment: from traditional Chinese herbal medicine to the liposome delivery system. , 2022, 1, .		4
426	A tumor microenvironment preoperative nomogram for prediction of lymph node metastasis in bladder cancer. Frontiers in Oncology, 0, 12, .	2.8	1
427	The iron-modulating hormone hepcidin is upregulated and associated with poor survival outcomes in renal clear cell carcinoma. Frontiers in Pharmacology, 0, 13, .	3.5	3
428	Establishment and validation of a redox-related long non-coding RNAs prognostic signature in head and neck squamous cell carcinoma. Scientific Reports, 2022, 12, .	3.3	2
429	Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. Cancers, 2023, 15, 50.	3.7	5
430	Maslinic acid exerts anticancer effects by targeting cancer hallmarks. Phytomedicine, 2023, 110, 154631.	5.3	4
431	Brain borders at the central stage of neuroimmunology. Nature, 2022, 612, 417-429.	27.8	53
432	Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. European Journal of Cell Biology, 2023, 102, 151284.	3.6	8
433	Multifunctional nanoparticle for cancer therapy. MedComm, 2023, 4, .	7.2	8
434	Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control. Frontiers in Oncology, 0, 12, .	2.8	0
435	Immunotherapy Assessment: A New Paradigm for Radiologists. Diagnostics, 2023, 13, 302.	2.6	1
436	Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592211480.	3.2	10
437	Identification and validation of a muscle failure index to predict prognosis and immunotherapy in lung adenocarcinoma through integrated analysis of bulk and single-cell RNA sequencing data. Frontiers in Immunology, 0, 13, .	4.8	2



#	ARTICLE	IF	CITATIONS
438	Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	4
439	The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
442	SPOCK1 and POSTN are valuable prognostic biomarkers and correlate with tumor immune infiltrates in colorectal cancer. <i>BMC Gastroenterology</i> , 2023, 23, .	2.0	4
443	Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
444	Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
445	The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
446	Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe. <i>Life Sciences</i> , 2023, 315, 121361.	4.3	10
447	Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatment. <i>Coordination Chemistry Reviews</i> , 2023, 480, 215027.	18.8	23
448	A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer. , 2023, 40, .		2
449	miR-29c Suppresses the Malignant Phenotype of Hepatocellular Carcinoma Cells In Vitro by Mediating TPX2 Associated with Immune Infiltration. <i>Digestive Diseases and Sciences</i> , 0, , .	2.3	0
450	Development and validation of a combined metabolism and immune prognostic model in lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2022, 14, 4983-4997.	1.4	0
451	A comprehensive analysis of the FOX family for predicting kidney renal clear cell carcinoma prognosis and the oncogenic role of FOXG1. <i>Aging</i> , 2022, 14, 10107-10124.	3.1	5
452	Pharmacomicrobiomics in Anticancer Therapies: Why the Gut Microbiota Should Be Pointed Out. <i>Genes</i> , 2023, 14, 55.	2.4	5
453	Tumor-Infiltrating Lymphocytes in Localized Prostate Cancer: Do They Play an Important Role?. <i>Cureus</i> , 2023, , .	0.5	0
455	Heat Shock Proteins in Cancer Immunotherapy. , 2023, , 1-15.		0
456	ImmunopET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential. , 2023, , 1-34.		0
457	mRNAâ€”From COVID-19 Treatment to Cancer Immunotherapy. <i>Biomedicines</i> , 2023, 11, 308.	3.2	3
458	Progress of Endogenous and Exogenous Nanoparticles for Cancer Therapy and Diagnostics. <i>Genes</i> , 2023, 14, 259.	2.4	2

#	ARTICLE	IF	CITATIONS
459	Tumor immunology. , 2023, , 245-452.		0
460	T cell exhaustion in malignant gliomas. Trends in Cancer, 2023, 9, 270-292.	7.4	23
461	Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer. Frontiers in Endocrinology, 0, 14, .	3.5	1
462	Tumor-infiltrating lymphocytes and macrophages as a significant prognostic factor in biliary tract cancer. PLoS ONE, 2023, 18, e0280348.	2.5	1
463	Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma. Cancers, 2023, 15, 602.	3.7	10
464	Combined Cancer Immunotheranostic Nanomedicines: Delivery Technologies and Therapeutic Outcomes. ACS Omega, 2023, 8, 4491-4507.	3.5	3
465	Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunology, Immunotherapy, 2023, 72, 1381-1394.	4.2	3
466	Bioinformatic analysis of the obesity paradox and possible associated factors in colorectal cancer using TCGA cohorts. Journal of Cancer, 2023, 14, 379-392.	2.5	2
467	Chromatin Regulator-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Breast Cancer. Journal of Oncology, 2023, 2023, 1-12.	1.3	1
468	Introduction on Cancer Immunotherapy. , 2023, , 1-27.		0
469	Exosomes as drug delivery system in gastrointestinal cancer. Frontiers in Oncology, 0, 12, .	2.8	2
470	Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma. Npj Genomic Medicine, 2023, 8, .	3.8	7
471	Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer. Healthcare (Switzerland), 2023, 11, 304.	2.0	5
472	Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. Frontiers in Immunology, 0, 13, .	4.8	4
473	Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer. Journal of Ovarian Research, 2023, 16, .	3.0	6
474	The Sesquiterpene Lactone-Rich Fraction of Inula helenium L. Enhances the Antitumor Effect of Anti-PD-1 Antibody in Colorectal Cancer: Integrative Phytochemical, Transcriptomic, and Experimental Analyses. Cancers, 2023, 15, 653.	3.7	3
475	Synthesis and Biological Evaluation of Potential Oncoimmunomodulator Agents. International Journal of Molecular Sciences, 2023, 24, 2614.	4.1	5
476	Developments of PROTACs technology in immune-related diseases. European Journal of Medicinal Chemistry, 2023, 249, 115127.	5.5	4

#	ARTICLE	IF	CITATIONS
477	An evaluation of the suitability, readability, quality, and usefulness of online resources for patients with cancer receiving immunotherapy. Patient Education and Counseling, 2023, 110, 107640.	2.2	1
478	Immunotherapy: Targeting Cancer Cells. Biological and Medical Physics Series, 2023, , 179-217.	0.4	0
479	Cancer proteomics, current status, challenges, and future outlook. , 2023, , 363-379.		1
480	Optimization of cancer immunotherapy on the basis of programmed death ligandâ€”1 distribution and function. British Journal of Pharmacology, 2024, 181, 257-272.	5.4	4
481	Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses. Frontiers in Pharmacology, 0, 14, .	3.5	3
482	Comprehensive analysis of novel cancer prediction genes and tumor microenvironment infiltration in colon cancer. Clinical and Translational Oncology, 0, , .	2.4	0
483	Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. Immunotherapy, 2023, 15, 417-428.	2.0	0
484	Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. Cancer Letters, 2023, 562, 216167.	7.2	5
485	Histone methyltransferase KMT2D promotes prostate cancer progression through paracrine IL-6 signaling. Biochemical and Biophysical Research Communications, 2023, 655, 35-43.	2.1	3
486	Extracellular vesicles as next generation immunotherapeutics. Seminars in Cancer Biology, 2023, 90, 73-100.	9.6	16
487	NIR-II Light-driven genetically edited nanoparticles with inherent CRT-inducing capability for macrophage-mediated immunotherapy. Nano Today, 2023, 50, 101857.	11.9	4
488	Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients. Computers in Biology and Medicine, 2023, 159, 106866.	7.0	0
489	GABAergic signaling as a potential therapeutic target in cancers. Biomedicine and Pharmacotherapy, 2023, 161, 114410.	5.6	3
490	CD163 Monoclonal Antibody Modified Polymer Prodrug Nanoparticles for Targeting Tumor-Associated Macrophages (TAMs) to Enhance Anti-Tumor Effects. Pharmaceutics, 2023, 15, 1241.	4.5	0
491	Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy. Seminars in Cancer Biology, 2023, 90, 57-72.	9.6	11
495	Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy. Materials Today Bio, 2023, 19, 100555.	5.5	4
496	Chronic stress in solid tumor development: from mechanisms to interventions. Journal of Biomedical Science, 2023, 30, .	7.0	8
497	Therapeutic Vaccination for HPV-Mediated Cancers. Current Otorhinolaryngology Reports, 2023, 11, 44-61.	0.5	8

#	ARTICLE	IF	CITATIONS
498	Expression of the prognostic marker $\alpha$ 8 correlates with the immune signature and epithelial-mesenchymal transition in breast cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2023, 37, .	2.1	5
499	Comprehensive landscape of the IPAF inflammasomes in pan-cancer: A bulk omics research and single-cell sequencing validation. <i>Computers in Biology and Medicine</i> , 2023, 155, 106622.	7.0	0
500	Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images. <i>Oncology Research</i> , 2022, 30, 243-258.	1.5	0
501	Recent advances in long-acting drug delivery systems for anticancer drug. <i>Advanced Drug Delivery Reviews</i> , 2023, 194, 114724.	13.7	30
502	Tumor-immune microenvironment lab chip integrating liquid-dielectrophoresis operation. <i>Japanese Journal of Applied Physics</i> , 2023, 62, SC1049.	1.5	0
503	Immunogenic antitumor potential of Prakasine nanoparticles in zebrafish by gene expression stimulation. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2023, 51, 41-56.	2.8	1
504	The application of carbon dots in tumor immunotherapy: Researches and prospects. , 2023, 2, .		3
505	Boosting Checkpoint Immunotherapy with Biomaterials. <i>ACS Nano</i> , 2023, 17, 3225-3258.	14.6	20
506	Using temporal heatmaps to identify worthwhile articles on immune checkpoint blockade for melanoma (ICBM) in Mainland China, Hong Kong, and Taiwan since 2000: A bibliometric analysis. <i>Medicine (United States)</i> , 2023, 102, e32797.	1.0	6
507	A Multi-Omics Analysis of NASH-Related Prognostic Biomarkers Associated with Drug Sensitivity and Immune Infiltration in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 1286.	2.4	0
508	Pain-Related Gene Solute Carrier Family 24 Member 3 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma: A Study via Integrated Bioinformatics Analyses and Experimental Verification. <i>Computational and Mathematical Methods in Medicine</i> , 2023, 2023, 1-23.	1.3	0
509	A novel gene signature related to oxidative stress predicts the prognosis in clear cell renal cell carcinoma. <i>PeerJ</i> , 0, 11, e14784.	2.0	3
510	Beta glucan as an immune stimulant in tumor microenvironment – Insight into lessons and promises from past decade. <i>International Journal of Biological Macromolecules</i> , 2023, 234, 123617.	7.5	7
511	A bibliometric analysis of Mediterranean diet on cancer from 2012 to 2021. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	2
512	CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	4
513	Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3270.	4.1	2
514	Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. <i>World Journal of Gastroenterology</i> , 0, 29, 1054-1075.	3.3	18
515	Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. <i>Molecular Cancer</i> , 2023, 22, .	19.2	36

#	ARTICLE	IF	CITATIONS
517	Integrated analysis reveals the microenvironment of non-small cell lung cancer and a macrophage-related prognostic model. <i>Translational Lung Cancer Research</i> , 2023, 12, 277-294.	2.8	0
518	Cisplatin and Albumin-Based Goldâ€“Cisplatin Nanoparticles Enhance Ablative Radiation Therapyâ€“Induced Antitumor Immunity in Local and Distant Tumor Microenvironment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 116, 1135-1149.	0.8	3
519	Multi-Omics Analysis Reveals Intratumor Microbes as Immunomodulators in Colorectal Cancer. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	6
520	Glutathione-responsive nanoplatform for intra/extracellular lactate exhaustion to enhance antitumor immunotherapy. <i>Materials and Design</i> , 2023, 227, 111750.	7.0	1
521	ERBB3 mediates the PI3K/AKT/mTOR pathway to alter the epithelialâ€“mesenchymal transition in cervical cancer and predict immunity filtration outcome. <i>Experimental and Therapeutic Medicine</i> , 2023, 25, .	1.8	3
522	Hydrogel systems for targeted cancer therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	4.1	10
523	The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years. <i>Current Medical Imaging</i> , 2023, 19, .	0.8	1
524	Natural Killer Cell-Derived Extracellular Vesicles as a Promising Immunotherapeutic Strategy for Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4026.	4.1	5
525	Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 135-145.	2.4	6
526	Effect of celecoxib plus standard chemotherapy on cancer prognosis: A systematic review and metaâ€“analysis. <i>European Journal of Clinical Investigation</i> , 2023, 53, .	3.4	4
527	A Comprehensive and Systematic Analysis Revealed the Role of ADAR1 in Pan-Cancer Prognosis and Immune Implications. <i>Disease Markers</i> , 2023, 2023, 1-16.	1.3	0
528	Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	4
529	Hafnium oxide nanoparticles coated ATR inhibitor to enhance the radiotherapy and potentiate antitumor immune response. <i>Chemical Engineering Journal</i> , 2023, 461, 142085.	12.7	4
530	Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors. <i>Molecular Pharmaceutics</i> , 2023, 20, 1975-1989.	4.6	2
531	Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma. <i>Thoracic Cancer</i> , 2023, 14, 893-912.	1.9	2
533	Tumor-infiltrating lymphocyte therapy: an overview. <i>Journal of Applied Biotechnology &amp; Bioengineering</i> , 2023, 10, 32-35.	0.1	0
534	Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
535	Effective Reversal of Macrophage Polarization by Inhibitory Combinations Predicted by a Boolean Proteinâ€“Protein Interaction Model. <i>Biology</i> , 2023, 12, 376.	2.8	1

#	ARTICLE	IF	CITATIONS
536	Proteomics: A modern tool for identifying therapeutic targets in different types of carcinomas. , 2023, , 333-362.		0
537	Smart Polymeric Nanoparticles in Cancer Immunotherapy. Pharmaceutics, 2023, 15, 775.	4.5	10
538	Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy. Cell Chemical Biology, 2023, 30, 235-247.e12.	5.2	27
539	Harnessing the power of memory-like NK cells to fight cancer. Clinical and Experimental Immunology, 2023, 212, 212-223.	2.6	1
540	Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis. Frontiers in Immunology, 0, 14, .	4.8	3
541	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancerâ€”Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. Cancers, 2023, 15, 1642.	3.7	4
542	Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies. Cells, 2023, 12, 841.	4.1	3
543	Boosting immunogenic cell death via hollow MnO2-based multiple stimuli-responsive drug delivery systems for improved cancer immunotherapy. Cancer Nanotechnology, 2023, 14, .	3.7	2
544	I kappa B kinase interacting protein as a promising biomarker in pan-cancer: A multi-omics analysis. Frontiers in Genetics, 0, 14, .	2.3	0
545	Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment. Pharmacological Research, 2023, 190, 106733.	7.1	21
546	Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. Journal of Personalized Medicine, 2023, 13, 526.	2.5	5
547	Future of Artificial Intelligence Applications in Cancer Care: A Global Cross-Sectional Survey of Researchers. Current Oncology, 2023, 30, 3432-3446.	2.2	6
548	SMC4, a novel tumor prognostic marker and potential tumor therapeutic target. Frontiers in Oncology, 0, 13, .	2.8	1
549	Cancer Proteomics for Cellular Dysfunction: Insights and Trends. Current Pharmaceutical Design, 2023, 29, 697-712.	1.9	0
550	SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NFâ€”B signaling and enhancing nature killer cellâ€”mediated tumor surveillance. Experimental and Therapeutic Medicine, 2023, 25, .	1.8	0
554	Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. Journal of Thoracic Oncology, 2023, 18, 869-881.	1.1	14
555	Applications of immune checkpoint inhibitors (ICIs) in the medical fields. , 0, 36, 321-330.		0
556	Gag-derived VLPs and the delivery of CRISPR-Cas9 system in Gene and Cell Therapies. , 0, 36, 1511-1516.		0

#	ARTICLE	IF	CITATIONS
557	The Potential Use of Exosomes in Anti-Cancer Effect Induced by Polarized Macrophages. <i>Pharmaceutics</i> , 2023, 15, 1024.	4.5	1
558	Integrating single-cell analysis and machine learning to create glycosylation-based gene signature for prognostic prediction of uveal melanoma. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	21
559	The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker. <i>Aging</i> , 2023, 15, 2136-2157.	3.1	1
560	Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology. <i>Genes and Diseases</i> , 2024, 11, 807-818.	3.4	4
561	Risk stratification based on DNA damage-repair-related signature reflects the microenvironmental feature, metabolic status and therapeutic response of breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
562	An Immune-Related Gene Signature for Determining Tumor Prognosis Based on Machine Learning. , 2023, , 1-18.		0
563	Nanomedicine for Tâ€Cell Mediated Immunotherapy. <i>Advanced Materials</i> , 0, , .	21.0	6
564	CiTSA: a comprehensive platform provides experimentally supported signatures of cancer immunotherapy and analysis tools based on bulk and scRNA-seq data. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	0
566	Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
567	The EBV Gastric Cancer Resource (EBV-GCR): A Suite of Tools for Investigating EBV-Associated Human Gastric Carcinogenesis. <i>Viruses</i> , 2023, 15, 853.	3.3	2
568	CD226 identifies functional CD8+T cells in the tumor microenvironment and predicts a better outcome for human gastric cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
570	Precision Killing of M2 Macrophages with Phage-Displayed Peptide-Photosensitizer Conjugates. <i>Cancers</i> , 2023, 15, 2009.	3.7	1
571	Pan-cancer analysis of <i>BRK1</i> as a potential immunotherapeutic target. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-23.	6.2	1
572	Pan-cancer analysis reveals the associations between MMP13 high expression and carcinogenesis and its value as a serum diagnostic marker. <i>Aging</i> , 2023, 15, 2115-2135.	3.1	0
573	Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity. <i>Molecular Therapy</i> , 2023, 31, 1938-1959.	8.2	2
574	The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions. <i>Cancers</i> , 2023, 15, 2101.	3.7	3
575	Ferritin in cancer therapy: A pleiotropic tumoraffin nanocageâ€based transport. <i>Cancer Medicine</i> , 2023, 12, 11570-11588.	2.8	5
578	Anchoring Filament Protein Ladinin-1 is an Immunosuppressive Microenvironment and Cold Tumor Correlated Prognosticator in Lung Adenocarcinoma. <i>Biochemical Genetics</i> , 0, , .	1.7	0



#	ARTICLE	IF	CITATIONS
579	Pan-cancer analysis of super enhancer-induced PRR7-AS1 as a potential prognostic and immunological biomarker. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	0
580	Versatile biomimetic nanomedicine for treating cancer and inflammation disease. <i>Medical Review</i> , 2023, 3, 123-151.	1.2	0
581	Prophylactic antineoplastic activity of <i>Toxoplasma gondii</i> RH derived antigen against ehrlich solid carcinoma with evidence of shared antigens by comparative immunoblotting. <i>Infectious Agents and Cancer</i> , 2023, 18, .	2.6	2
582	Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study. <i>Cancers</i> , 2023, 15, 2217.	3.7	1
583	Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. <i>British Journal of Cancer</i> , 2023, 129, 185-203.	6.4	6
584	Discovery of First-in-Class Small Molecule Inhibitors of Lymphocyte Activation Gene 3 (LAG-3). <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 629-635.	2.8	6
585	Bayesian network enables interpretable and state-of-the-art prediction of immunotherapy responses in cancer patients. , 0, , .		0
586	Autoimmune encephalitis. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 445-467.	0.1	0
587	Pan-cancer analysis reveals IGFL2 as a potential target for cancer prognosis and immunotherapy. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
588	Combination Therapy of Radiation and Hyperthermia, Focusing on the Synergistic Anti-Cancer Effects and Research Trends. <i>Antioxidants</i> , 2023, 12, 924.	5.1	5
589	Investigation of Diagnostic and Prognostic Value of CLEC4M of Non-Small Cell Lung Carcinoma Associated with Immune Microenvironment. <i>International Journal of General Medicine</i> , 0, Volume 16, 1317-1332.	1.8	0
590	Immune-related mechanisms and immunotherapy in extragonadal germ cell tumors. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
591	Low-intensity focused ultrasound targeted microbubble destruction reduces tumor blood supply and sensitizes anti-PD-L1 immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	4.1	4
592	Ovarian cancer-associated immune exhaustion involves SPP1+ T cell and NKT cell, symbolizing more malignant progression. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
593	Overview and countermeasures of cancer burden in China. <i>Science China Life Sciences</i> , 2023, 66, 2515-2526.	4.9	11
594	Therapeutic Potential of <i>Clostridium novyi</i> -NT in Cancer: Current Knowledge and Future Perspectives. <i>Current Cancer Drug Targets</i> , 2023, 23, 682-696.	1.6	1
595	Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma. <i>BMC Medical Genomics</i> , 2023, 16, .	1.5	1
596	CILP2: A prognostic biomarker associated with immune infiltration in colorectal cancer. <i>Heliyon</i> , 2023, 9, e15535.	3.2	1



#	ARTICLE	IF	CITATIONS
597	Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation. <i>Journal of Controlled Release</i> , 2023, 357, 531-544.	9.9	7
598	Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	2
599	Application of Nanotechnology in Therapeutic Cancer Vaccines. <i>Advanced NanoBiomed Research</i> , 2023, 3, .	3.6	5
600	Molecular imaging of innate immunity and immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2023, 198, 114865.	13.7	3
601	CCNF is a potential pancancer biomarker and immunotherapy target. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
602	A Pan-cancer Analysis to Determine the Prognostic Analysis and Immune Infiltration of HSPA5. <i>Current Cancer Drug Targets</i> , 2024, 24, 14-27.	1.6	1
604	Cholesterol Metabolism Modulation Nanoplatform Improves Photoacoustic Immunotherapeutic Effect in Oral Squamous Cell Carcinoma. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	2
605	Ubiquitination-related biomarkers in metastatic melanoma patients and their roles in tumor microenvironment. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
606	The role of immunotherapy in lung cancer: Actual scenery. , 2023, 2, 45-51.		0
607	A pan-cancer analysis of ABI3BP: a potential biomarker for prognosis and immunoinfiltration. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
608	Carbon dot-based nanomaterials: a promising future nano-platform for targeting tumor-associated macrophages. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
609	A pan-cancer analysis of the expression and molecular mechanism of DHX9 in human cancers. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	1
611	A novel pyroptosis-associated lncRNA LINC01133 promotes pancreatic adenocarcinoma development via miR-30b-5p/SIRT1 axis. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 1381-1398.	4.4	2
612	Cuproptosis Regulates Microenvironment and Affects Prognosis in Prostate Cancer. <i>Biological Trace Element Research</i> , 2024, 202, 99-110.	3.5	3
613	Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma. <i>Functional and Integrative Genomics</i> , 2023, 23, .	3.5	1
614	Clinical case of complications of immunotherapy “encephalitis”. <i>Journal of Modern Oncology</i> , 2023, 25, 140-144.	0.3	0
616	A perspective on a precision approach to pain in cancer; moving beyond opioid therapy. <i>Disability and Rehabilitation</i> , 0, , 1-10.	1.8	0
617	The past, present, and future of immunotherapy for endometrial adenocarcinoma. , 2023, 40, .		1

#	ARTICLE	IF	CITATIONS
618	Checkpoint Inhibitor-Induced Colitis: An Update. <i>Biomedicines</i> , 2023, 11, 1496.	3.2	5
619	A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing. <i>BMC Bioinformatics</i> , 2023, 24, .	2.6	0
620	Integrated analysis of single-cell and bulk RNA sequencing data reveals an immunostimulatory microenvironment in tumor thrombus of osteosarcoma. <i>Oncogenesis</i> , 2023, 12, .	4.9	1
621	Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition. <i>Journal of Clinical Medicine</i> , 2023, 12, 3725.	2.4	1
622	The role of circular RNA in tumor microenvironment and immunotherapy. <i>International Journal of Biological Macromolecules</i> , 2023, 242, 124929.	7.5	0
623	Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. <i>Nature Medicine</i> , 2023, 29, 1550-1562.	30.7	48
624	Comprehensive analysis of the prognosis and immune effect of the oncogenic protein Four Jointed Box 1. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
626	Illuminating and Radiosensitizing Tumors with 2DG-Bound Gold-Based Nanomedicine for Targeted CT Imaging and Therapy. <i>Nanomaterials</i> , 2023, 13, 1790.	4.1	2
627	Pan-cancer analysis of the intervertebral-disc-degeneration-related innate immunity gene NAIP. <i>PLoS ONE</i> , 2023, 18, e0286647.	2.5	0
628	The application and research progress of anti-angiogenesis therapy in tumor immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
629	PCNT is a prognostic biomarker correlated with tumor immune microenvironment in hepatocellular carcinoma and promotes tumor progression by inhibiting cell cycle arrest. <i>Aging</i> , 2023, 15, 4122-4143.	3.1	0
630	The current advances of lncRNAs in breast cancer immunobiology research. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
631	B7-H7: A potential target for cancer immunotherapy. <i>International Immunopharmacology</i> , 2023, 121, 110403.	3.8	1
632	High expression of GPR176 predicts poor prognosis of gastric cancer patients and promotes the proliferation, migration, and invasion of gastric cancer cells. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
634	The biological roles of CD24 in ovarian cancer: old story, but new tales. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
635	Editorial: Progress of programmed cell death in antitumor immunity. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
636	Glutamine metabolism genes prognostic signature for stomach adenocarcinoma and immune infiltration: potential biomarkers for predicting overall survival. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
637	Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in liver metastasis lesions after colon radical operation. <i>BMC Cancer</i> , 2023, 23, .	2.6	0

#	ARTICLE	IF	CITATIONS
638	Integrated bioinformatics and experimental validation reveal the role of JARID2 in ovarian cancer. Epigenomics, 0, , .	2.1	0
639	Nanomaterials in tumor immunotherapy: new strategies and challenges. Molecular Cancer, 2023, 22, .	19.2	17
640	Integrated Single-Cell and Transcriptome Sequencing Analyses Identify Dipeptidase 2 as an Immune-Associated Prognostic Biomarker for Lung Adenocarcinoma. Pharmaceuticals, 2023, 16, 871.	3.8	0
641	Cross-talk of RNA modification writers describes tumor stemness and microenvironment and guides personalized immunotherapy for gastric cancer. Aging, 0, , .	3.1	0
642	Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity. Frontiers in Immunology, 0, 14, .	4.8	1
643	Anti-Tumor Effects of Cisplatin Synergist in Combined Treatment with Clostridium Novyi-NT Spores Against Hypoxic Microenvironments in a Mouse Model of Cervical Cancer Caused by TC-1 Cell Line. Advanced Pharmaceutical Bulletin, 0, , .	1.4	0
644	Î±-Lipoic acid alleviates myocardial injury and induces M2b macrophage polarization after myocardial infarction via HMGB1/NF-κB signaling pathway. International Immunopharmacology, 2023, 121, 110435.	3.8	4
645	Recent Advances in Perfluorocarbon-Based Delivery Systems for Cancer Theranostics. Molecular Pharmaceutics, 2023, 20, 3254-3277.	4.6	5
646	Cellular Membrane Componentsâ€Mediated Cancer Immunotherapeutic Platforms. Macromolecular Bioscience, 2023, 23, .	4.1	2
647	Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis. Chemotherapy, 2023, 68, 197-209.	1.6	0
648	Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers. Frontiers in Immunology, 0, 14, .	4.8	1
649	LncRNA AL161431.1 predicts prognosis and drug response in head and neck squamous cell carcinoma. Frontiers in Oncology, 0, 13, .	2.8	0
650	A Bibliometric Analysis of Melanoma Treated with Vaccinations Research from 2013 to 2023: A Comprehensive Review of the Literature. Vaccines, 2023, 11, 1113.	4.4	0
651	Integrative analysis of circadian clock with prognostic and immunological biomarker identification in ovarian cancer. Frontiers in Molecular Biosciences, 0, 10, .	3.5	1
652	Pharmacological effects and mechanisms of paeonol on antitumor and prevention of side effects of cancer therapy. Frontiers in Pharmacology, 0, 14, .	3.5	2
653	Expression of cancerâ€testis antigens in the immune microenvironment of nonâ€small cell lung cancer. Molecular Oncology, 2023, 17, 2603-2617.	4.6	1
654	A bibliometric analysis of CiteSpace software-based immunotherapy for the treatment of diffuse large B-cell lymphoma. Asian Journal of Oncology, 0, 9, 1-10.	0.2	0
655	NK cells encapsulated in micro/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy. Biomaterials Research, 2023, 27, .	6.9	8

#	ARTICLE	IF	CITATIONS
656	Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	17.0	3
657	MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration. <i>Discover Oncology</i> , 2023, 14, .	2.1	2
658	Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients. <i>Seminars in Immunology</i> , 2023, 69, 101796.	5.6	0
661	Systemic Delivery of a STING Agonistâ€Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis. <i>Small</i> , 2023, 19, .	10.0	3
663	DUSP10 is a novel immune-related biomarker connected with survival and cellular proliferation in lower-grade glioma. <i>Aging</i> , 0, , .	3.1	0
664	A Novel Strategy for Screening Tumor-Specific Variable Domain of Heavy-Chain Antibodies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10804.	4.1	0
665	Abscopal effect observed in visceral and osseous metastases after liver SBRT in combination with nivolumab and relatlimab for sinonasal mucosal melanomaâ€a case report. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
666	Development of a high-throughput TR-FRET screening assay for LAG-3/FGL1 interaction. <i>SLAS Discovery</i> , 2023, 28, 188-192.	2.7	6
667	MMP9 and TYROBP affect the survival of circulating tumor cells in clear cell renal cell carcinoma by adapting to tumor immune microenvironment. <i>Scientific Reports</i> , 2023, 13, .	3.3	3
668	Analysis of thymic generation of shared Tâ€cell receptor Î± repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wildâ€type antigens. <i>Cancer Medicine</i> , 2023, 12, 13486-13496.	2.8	0
670	Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma. <i>BMC Cancer</i> , 2023, 23, .	2.6	3
671	CircRNAs in tumor immunity and immunotherapy: Perspectives from innate and adaptive immunity. <i>Cancer Letters</i> , 2023, 564, 216219.	7.2	8
672	The Role of Hypoxia and Cancer Stem Cells in Development of Glioblastoma. <i>Cancers</i> , 2023, 15, 2613.	3.7	7
673	Shedding light on a mysterious link between <i>Toxoplasma gondii</i> and cancer: A review. <i>Experimental Parasitology</i> , 2023, 250, 108544.	1.2	2
674	Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	7
675	Multi-shell structured upconversion nanocarriers that combine IDO inhibitor-induced immunotherapy with NIR-triggered photodynamic therapy for deep tumors. <i>Biomaterials Science</i> , 2023, 11, 4684-4699.	5.4	1
676	Establishment and Validation of a Novel Risk Score for Hepatocellular Carcinoma Based on Bile Acid and Bile Salt Metabolism-Related Genes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 8597.	4.1	1
678	Oxidative stress in the tumor microenvironment in gastric cancer and its potential role in immunotherapy. <i>FEBS Open Bio</i> , 2023, 13, 1238-1252.	2.3	1

#	ARTICLE	IF	CITATIONS
679	Recent Advances in Molecular Mechanisms of Cancer Immunotherapy. <i>Cancers</i> , 2023, 15, 2721.	3.7	9
680	ARHGAP39 is a prognostic biomarker involved in immune infiltration in breast cancer. <i>BMC Cancer</i> , 2023, 23, .	2.6	1
681	Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer. <i>Cancer Cell International</i> , 2023, 23, .	4.1	0
682	SPARTIN: a Bayesian method for the quantification and characterization of cell type interactions in spatial pathology data. <i>Frontiers in Genetics</i> , 0, 14, .	2.3	2
683	Exploring the relationship between abnormally high expression of NUP205 and the clinicopathological characteristics, immune microenvironment, and prognostic value of lower-grade glioma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
684	Significance of Immunogenic Cell Death-Related Prognostic Gene Signature in Cervical Cancer Prognosis and Anti-Tumor Immunity. <i>Journal of Inflammation Research</i> , 0, Volume 16, 2189-2207.	3.5	0
685	Establishment and validation of a ferroptosis-related signature predicting prognosis and immunotherapy effect in colon cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
686	Pan-cancer analysis reveals the prognostic and immunotherapeutic value of cytoskeleton-associated protein 2-like. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
687	Ultrasoundâ€Triggered Cascade Amplification of Nanotherapy. <i>Advanced Materials</i> , 2023, 35, .	21.0	6
688	A novel His-tag-binding aptamer for recombinant protein detection and T cell-based immunotherapy. <i>Talanta</i> , 2023, 263, 124722.	5.5	3
689	The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors. <i>Current Oncology</i> , 2023, 30, 5279-5298.	2.2	0
690	Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	9.1	8
691	The DEAD-box RNA helicase, DDX60, Suppresses immunotherapy and promotes malignant progression of pancreatic cancer. <i>Biochemistry and Biophysics Reports</i> , 2023, 34, 101488.	1.3	1
692	Complementary roles of EP2 and EP4 receptors in malignant glioma. <i>British Journal of Pharmacology</i> , 2023, 180, 2623-2640.	5.4	4
693	Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects. <i>Pharmaceuticals</i> , 2023, 16, 923.	3.8	3
694	Research progress on carbon materials in tumor photothermal therapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 165, 115070.	5.6	6
695	Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	3.9	0
696	Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 11351-11368.	2.5	3

#	ARTICLE	IF	CITATIONS
697	Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2023, 15, 1868.	4.5	5
698	How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature. <i>International Journal of Nanomedicine</i> , 0, Volume 18, 3663-3694.	6.7	0
700	N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
701	Pan-cancer analysis of the prognostic and immunological role of nucleophosmin/nucleoplasmin 3 (NPM3) and its potential significance in lung adenocarcinoma. , 2023, 1, 238-252.		0
702	Understanding and Overcoming Immunosuppression Shaped by Cancer Stem Cells. <i>Cancer Research</i> , 2023, 83, 2096-2104.	0.9	2
704	Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions. <i>Cancers</i> , 2023, 15, 3506.	3.7	6
705	Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. <i>Cancer Cell</i> , 2023, 41, 1407-1426.e9.	16.8	7
706	Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer. <i>Aging</i> , 2023, 15, 6302-6330.	3.1	0
707	Engineering exosomes as nanocarriers traverse the blood-brain barrier for theranostics against glioblastoma: Opportunities and challenges. , 2023, 1, 100006.		0
709	Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis. <i>The Lancet Regional Health - Western Pacific</i> , 2023, 38, 100841.	2.9	2
710	Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10A/B, and induces TRAIL-mediated cell death in colorectal cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2023, 675, 33-40.	2.1	1
711	Innate Immunity in Cancer Biology and Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11233.	4.1	1
712	The role of immune subtyping in glioma mRNA vaccine development. <i>Immunotherapy</i> , 2023, 15, 1057-1072.	2.0	1
713	The roles of inflammasomes in cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
714	A global database for modeling tumor-immune cell communication. <i>Scientific Data</i> , 2023, 10, .	5.3	1
715	Bispecific antibody targeting TGF- $\beta$ 2 and PD-L1 for synergistic cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	8
717	Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events. , 2023, 40, .		4
718	Necroptosis in the sarcoma immune microenvironment: From biology to therapy. <i>International Immunopharmacology</i> , 2023, 122, 110603.	3.8	1

#	ARTICLE	IF	CITATIONS
719	Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. International Journal of Molecular Sciences, 2023, 24, 11504.	4.1	3
720	Molecular subtyping and prognostic risk characterization of head and neck squamous cell carcinoma based on lysosome-related genes. Medicine (United States), 2023, 102, e34275.	1.0	0
721	Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies. Advances in Experimental Medicine and Biology, 2023, , 85-110.	1.6	0
722	Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma. Cancers, 2023, 15, 3726.	3.7	1
723	Identification and validation of a novel overall survival prediction model for immune-related genes in bone metastases of prostate cancer. Aging, 0, , .	3.1	0
725	Reversal of the immunosuppressive tumor microenvironment via platinum-based neoadjuvant chemotherapy in cervical cancer. , 2024, 2, 38-49.		0
726	Immune modulation during anti-cancer radio(immuno)therapy. International Review of Cell and Molecular Biology, 2023, , .	3.2	0
727	Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability. International Journal of Molecular Sciences, 2023, 24, 11887.	4.1	7
728	Supramolecular Immunotherapy on Diversiform Immune Cells. Journal of Materials Chemistry B, 0, , .	5.8	0
729	Dissociated response to PD-1 inhibitors combined with radiotherapy in patients with advanced metastatic solid tumors: a single-center experience. World Journal of Surgical Oncology, 2023, 21, .	1.9	0
730	Serpin Family A Member 1 Is Prognostic and Involved in Immunological Regulation in Human Cancers. International Journal of Molecular Sciences, 2023, 24, 11566.	4.1	0
731	Multifunctional 3D-printed scaffolds eradicate orthotopic osteosarcoma and promote osteogenesis via microwave thermo-chemotherapy combined with immunotherapy. Biomaterials, 2023, 301, 122236.	11.4	7
732	Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer. Frontiers in Immunology, 0, 14, .	4.8	0
734	Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Molecular Cancer, 2023, 22, .	19.2	5
735	The extracellular matrix “immune microenvironment crosstalk in cancer therapy: Challenges and opportunities. Matrix Biology, 2023, 121, 217-228.	3.6	2
736	The effect of m2 peptide targeted nanoliposomes containing crocin on induction of phenotypic change in tumor macrophages to M1 state. Life Sciences, 2023, 330, 121992.	4.3	0
737	Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment. International Journal of Nanomedicine, 0, Volume 18, 4329-4346.	6.7	2
738	The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?. Molecular Therapy - Oncolytics, 2023, 30, 227-237.	4.4	0



#	ARTICLE	IF	CITATIONS
739	Machine learning methods revealed the roles of immune-metabolism related genes in immune infiltration, stemness, and prognosis of neuroblastoma. Cancer Biomarkers, 2023, 38, 241-259.	1.7	1
740	Effect of tumor-infiltrating lymphocytes depending on the presence of postmastectomy radiotherapy on the prognosis in pT1-2N1M0 breast cancer. Frontiers in Oncology, 0, 13, .	2.8	0
741	Multi-Omics Analysis Elucidates The Immune And Intratumor Microbes Characteristics Of Ubiquitination Subtypes In Lung Adenocarcinoma. Translational Oncology, 2023, 36, 101754.	3.7	0
742	Immunosuppressive MFAP2+ cancer associated fibroblasts conferred unfavorable prognosis and therapeutic resistance in gastric cancer. Cellular Oncology (Dordrecht), 2024, 47, 55-68.	4.4	2
743	Lipidâ€based nanoparticles as drug delivery systems for cancer immunotherapy. MedComm, 2023, 4, .	7.2	1
744	Peptide-Based Therapeutic HPV Cancer Vaccine Synthesized via Bacterial Outer Membrane Vesicles. International Journal of Nanomedicine, 0, Volume 18, 4541-4554.	6.7	0
745	Amplifying â€eat me signalâ€by immunogenic cell death for potentiating cancer immunotherapy. Immunological Reviews, 2024, 321, 94-114.	6.0	6
746	Identification of co-expressed gene networks promoting CD8+ T cell infiltration and having prognostic value in uveal melanoma. BMC Ophthalmology, 2023, 23, .	1.4	0
747	An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma. Apoptosis: an International Journal on Programmed Cell Death, 0, , .	4.9	0
748	Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy. Biomedicine and Pharmacotherapy, 2023, 166, 115336.	5.6	1
749	Eosinophils in the tumor microenvironment: implications for cancer immunotherapy. Journal of Translational Medicine, 2023, 21, .	4.4	4
750	Identification of prognostic biomarkers of breast cancer based onâ€theâ€immune-related gene module. Autoimmunity, 2023, 56, .	2.6	1
751	Sonodynamic Cytokine Nanocomplexes with Specific Stimulation towards Effector T Cell for Combination Cancer Immunotherapy. Angewandte Chemie, 2023, 135, .	2.0	0
752	A new marker constructed from immune-related lncRNA pairs can be used to predict clinical treatment effects and prognosis: in-depth exploration of underlying mechanisms in HNSCC. World Journal of Surgical Oncology, 2023, 21, .	1.9	0
753	Sonodynamic Cytokine Nanocomplexes with Specific Stimulation towards Effector T Cell for Combination Cancer Immunotherapy. Angewandte Chemie - International Edition, 2023, 62, .	13.8	2
754	Long-acting microneedle formulations. Advanced Drug Delivery Reviews, 2023, 201, 115055.	13.7	8
755	Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions. International Journal of Molecular Sciences, 2023, 24, 12931.	4.1	7
756	Prognostic significance of the rho <sc>GTPase RHOV</sc> and its role in tumor immune cell infiltration: a comprehensive panâ€cancer analysis. FEBS Open Bio, 2023, 13, 2124-2146.	2.3	0



#	ARTICLE	IF	CITATIONS
757	Comprehensive analysis of m6A subtype classification for immune microenvironment of pituitary adenomas. <i>International Immunopharmacology</i> , 2023, 124, 110784.	3.8	0
758	The role of the symbiotic microecosystem in cancer: gut microbiota, metabolome, and host immunome. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
759	Influence of the Composition of Cationic Liposomes on the Performance of Cargo Immunostimulatory RNA. <i>Pharmaceutics</i> , 2023, 15, 2184.	4.5	1
760	Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets. <i>Biomedicines</i> , 2023, 11, 2361.	3.2	0
761	Exploring the relationship between lactate metabolism and immunological function in colorectal cancer through genes identification and analysis. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	1
762	Editorial: Cutaneous immunology. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	0
763	Cancer Vaccine Therapeutics: Limitations and Effectivenessâ€”A Literature Review. <i>Cells</i> , 2023, 12, 2159.	4.1	9
764	Harnessing Ag2S quantum dots with immune adjuvant for NIR-II fluorescence imaging-guided sonodynamic immunotherapy of colon cancer. <i>Chemical Engineering Journal</i> , 2023, 474, 145685.	12.7	0
765	The Impact of Metformin on Tumor-Infiltrated Immune Cells: Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13353.	4.1	2
766	Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors. <i>Medicinal Chemistry Research</i> , 2023, 32, 2089-2115.	2.4	2
767	Clusterin Is a Prognostic Biomarker of Lower-Grade Gliomas and Is Associated with Immune Cell Infiltration. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13413.	4.1	0
769	Leptin/lipopolysaccharide-treated dendritic cell vaccine improved cellular immune responses in an animal model of breast cancer. <i>Immunopharmacology and Immunotoxicology</i> , 2024, 46, 73-85.	2.4	0
770	CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
771	Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials. <i>Frontiers in Pharmacology</i> , 0, 14, .	3.5	0
772	Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (<scp>CAR</scp>) Tâ€¢cell therapy. <i>European Journal of Haematology</i> , 2024, 112, 102-110.	2.2	1
773	Neoantigenâ€¢Based Nanovaccine In Combination with Immune Checkpoint Inhibitors Abolish Postsurgical Tumor Recurrence and Metastasis. <i>Small</i> , 2023, 19, .	10.0	2
774	The Prognostic and Therapeutic Role of Histone Acetylation Modification in LIHC Development and Progression. <i>Medicina (Lithuania)</i> , 2023, 59, 1682.	2.0	0
775	Progress on Phage Display Technology: Tailoring Antibodies for Cancer Immunotherapy. <i>Viruses</i> , 2023, 15, 1903.	3.3	5

#	ARTICLE	IF	CITATIONS
776	A PD-1 Antibody-Conjugated PAMAM Dendrimer Nanosystem for Simultaneously Inhibiting Glycolysis and Promoting Immune Response in Fighting Breast Cancer. <i>Advanced Materials</i> , 2023, 35, .	21.0	6
777	Advancing Immunotherapies for HPV-Related Cancers: Exploring Novel Vaccine Strategies and the Influence of Tumor Microenvironment. <i>Vaccines</i> , 2023, 11, 1354.	4.4	1
778	First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators. <i>RSC Medicinal Chemistry</i> , 2023, 14, 1767-1777.	3.9	3
779	The Present and Future of Optic Pathway Glioma Therapy. <i>Cells</i> , 2023, 12, 2380.	4.1	1
780	Development of a prognostic model for anoikis and identifies hub genes in hepatocellular carcinoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
781	Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	4
782	The action and resistance mechanisms of Lenvatinib in liver cancer. <i>Molecular Carcinogenesis</i> , 2023, 62, 1918-1934.	2.7	1
783	Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes. <i>Lung Cancer</i> , 2023, 183, 107318.	2.0	1
784	Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	2
785	Proteomics in Oncology: Retrospect and Prospects. , 2023, , 243-269.		0
786	Dose-related immunomodulatory effects of recombinant TRAIL in the tumor immune microenvironment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	8.6	2
787	Heterogeneity of the tumor immune microenvironment and clinical interventions. <i>Frontiers of Medicine</i> , 2023, 17, 617-648.	3.4	0
788	A review on the impact of TRAIL on cancer signaling and targeting via phytochemicals for possible cancer therapy. <i>International Journal of Biological Macromolecules</i> , 2023, 253, 127162.	7.5	1
789	Revealing the role of regulatory T cells in the tumor microenvironment of lung adenocarcinoma: a novel prognostic and immunotherapeutic signature. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
790	Integration of single-cell RNA sequencing and bulk RNA transcriptome sequencing reveals a heterogeneous immune landscape and pivotal cell subpopulations associated with colorectal cancer prognosis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
791	Construction and comprehensive analysis of a novel prognostic signature associated with immunogenic cell death molecular subtypes in patients with bladder cancer. <i>Heliyon</i> , 2023, 9, e18848.	3.2	0
792	X-ray cross-complementing family: the bridge linking DNA damage repair and cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	0
793	Characterization of tumor microenvironment and tumor immunology based on the double-stranded RNA-binding protein related genes in cervical cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	0

#	ARTICLE	IF	CITATIONS
794	Deciphering the immune reaction leading to spontaneous melanoma regression: initial role of MHCII+ CD163 <sup>+</sup> macrophages. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3507-3521.	4.2	1
795	Role of immune related genes in predicting prognosis and immune response in patients with hepatocellular carcinoma. <i>Journal of Biochemical and Molecular Toxicology</i> , 2024, 38, .	3.0	0
796	How single-cell techniques help us look into lung cancer heterogeneity and immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
797	The role and participation of immune cells in the endometrial tumor microenvironment. , 2023, 251, 108526.		2
798	Systemic Inflammatory Disorders, Immunosuppressive Treatment and Increase Risk of Head and Neck Cancers—A Narrative Review of Potential Physiopathological and Biological Mechanisms. <i>Cells</i> , 2023, 12, 2192.	4.1	0
799	COIMMR: a computational framework to reveal the contribution of herbal ingredients against human cancer via immune microenvironment and metabolic reprogramming. <i>Briefings in Bioinformatics</i> , 2023, 24, .	6.5	2
800	Deciphering Treg cell roles in esophageal squamous cell carcinoma: a comprehensive prognostic and immunotherapeutic analysis. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	1
801	The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	5
802	Bioinformatics and machine learning were used to validate glutamine metabolism-related genes and immunotherapy in osteoporosis patients. <i>Journal of Orthopaedic Surgery and Research</i> , 2023, 18, .	2.3	3
803	Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4297-4322.	3.6	2
804	Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2024, 41, 35-84.	2.2	0
805	The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies. <i>Cell and Bioscience</i> , 2023, 13, .	4.8	2
806	Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine. <i>Current Issues in Molecular Biology</i> , 2023, 45, 8337-8358.	2.4	0
807	Tumor-infiltrating gamma delta T-cells reveal exhausted subsets with remarkable heterogeneity in colorectal cancer. <i>International Journal of Cancer</i> , 2023, 153, 1684-1697.	5.1	1
808	Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
809	Natural polysaccharides exert anti-tumor effects as dendritic cell immune enhancers. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
810	PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
811	Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 1767-1784.	3.7	1

#	ARTICLE	IF	CITATIONS
812	MEK inhibitors increase the mortality rate in mice with LPS-induced inflammation through IL-12-NO signaling. <i>Cell Death Discovery</i> , 2023, 9, .	4.7	0
813	Prognostic value of controlling nutritional status on clinical and survival outcomes in cancer patients treated with immunotherapy. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
814	Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet. <i>British Journal of Cancer</i> , 2023, 129, 1373-1382.	6.4	4
815	Gamma Delta T Cells: Role in Immunotherapy of Hepatocellular Carcinoma. <i>Critical Reviews in Oncogenesis</i> , 2023, , .	0.4	1
816	Clinical neutrophil-related gene helps treat bladder urothelial carcinoma. <i>Oncologie</i> , 2023, 25, 529-542.	0.7	0
818	Immune gene signatures as prognostic criteria for cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	0
819	Copper-instigated modulatory cell mortality mechanisms and progress in oncological treatment investigations. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
820	CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma. <i>Immunity</i> , 2023, 56, 2086-2104.e8.	14.3	9
821	Upregulated FADD is associated with poor prognosis, immune exhaustion, tumor malignancy, and immunotherapy resistance in patients with lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
823	Decoding the Complexity of Immuneâ€“Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy. <i>Cancers</i> , 2023, 15, 4188.	3.7	6
824	Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy. <i>ACS Nano</i> , 2023, 17, 16620-16632.	14.6	5
825	Prognostic value of GLCE and infiltrating immune cells in Ewing sarcoma. <i>Heliyon</i> , 2023, 9, e19357.	3.2	1
826	Targeting immune checkpoint pathways in melanoma: triumphs and challenges. <i>Future Drug Discovery</i> , 2023, 5, .	2.1	0
827	Analysis of a new therapeutic target and construction of a prognostic model for breast cancer based on ferroptosis genes. <i>Computers in Biology and Medicine</i> , 2023, 165, 107370.	7.0	1
828	Integrating bioinformatic analysis and detailed experiments reveal an <scp>EMT</scp>-related biomarker for clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 2023, 12, 19320-19336.	2.8	0
830	Icariin inhibits prostate cancer bone metastasis and destruction via suppressing TAM/CCL5-mediated osteoclastogenesis. <i>Phytomedicine</i> , 2023, 120, 155076.	5.3	2
831	The diagnostic or prognostic values of FADD in cancers based on panâ€“cancer analysis. <i>Biomedical Reports</i> , 2023, 19, .	2.0	0
832	Molecular classification and tumor microenvironment characteristics in pheochromocytomas. <i>ELife</i> , 0, 12, .	6.0	0

#	ARTICLE	IF	CITATIONS
835	Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward. <i>Neuro-Oncology</i> , 0, , .	1.2	0
836	The potential use and experimental validation of genomic instability-related lncRNA in pancreatic carcinoma. <i>Medicine (United States)</i> , 2023, 102, e35300.	1.0	0
837	CAR T cells and dendritic cells: vaccinomics perspectives. <i>International Physical Medicine &amp; Rehabilitation Journal</i> , 2023, 8, 126-133.	0.1	0
838	Immune Cell Generation from Human-Induced Pluripotent Stem Cells: Current Status and Challenges. <i>Biochemistry</i> , 0, , .	1.2	0
839	Unveiling the growing significance of metabolism in modulating immune cell function: exploring mechanisms and implications; a review. <i>Annals of Medicine and Surgery</i> , 2023, 85, 5511-5522.	1.1	0
840	Tumor Microenvironment-Responsive Nanoparticles Amplifying STING Signaling Pathway for Cancer Immunotherapy. <i>Advanced Materials</i> , 2024, 36, .	21.0	2
841	Multifunctional nanogel based on carboxymethyl cellulose interfering with cellular redox homeostasis enhances phycocyanobilin photodynamic therapy. <i>Carbohydrate Polymers</i> , 2024, 323, 121416.	10.2	1
842	Pan-cancer analysis and experimental validation identify ndc1 as a potential immunological, prognostic and therapeutic biomarker in pancreatic cancer. <i>Aging</i> , 2023, 15, 9779-9796.	3.1	0
843	The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations. <i>World Neurosurgery</i> , 2023, , .	1.3	0
844	Role of immunotherapy in chondrosarcoma: A case report and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, .	3.2	1
846	Mapping the landscape of immunonutrition and cancer research: a comprehensive bibliometric analysis on behalf of NutriOnc Research Group. <i>International Journal of Surgery</i> , 2024, 110, 395-405.	2.7	0
847	Understanding cervical cancer at single-cell resolution. <i>Cancer Letters</i> , 2023, 576, 216408.	7.2	1
848	Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy. <i>Frontiers in Chemistry</i> , 0, 11, .	3.6	2
849	The integrated single-cell analysis developed an immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy. <i>Aging</i> , 2023, 15, 10305-10329.	3.1	3
850	Protracted complete response after limited checkpoint inhibitor dosing: A case report. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.5	0
851	A prognostic mathematical model based on tumor microenvironment-related genes expression for breast cancer patients. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
852	Combined signature of N7-methylguanosine regulators with their related genes and the tumor microenvironment: a prognostic and therapeutic biomarker for breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
853	Soy isoflavone genistein attenuates the efficacy of immune checkpoint therapy in C57BL/6 mice inoculated with B16F1 melanoma and a high PD-1 expression level reflects tumor resistance. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2024, 74, 57-62.	1.4	1

#	ARTICLE	IF	CITATIONS
855	Immune Cell Deconvolution Reveals Possible Association of $\beta$ T Cells with Poor Survival in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2023, 15, 4855.	3.7	0
856	Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study. <i>Medicine (United States)</i> , 2023, 102, e35423.	1.0	0
857	A phase-field model for non-small cell lung cancer under the effects of immunotherapy. <i>Mathematical Biosciences and Engineering</i> , 2023, 20, 18670-18694.	1.9	1
858	Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs. <i>Pharmaceutics</i> , 2023, 15, 2433.	4.5	1
859	PROS1, a clinical prognostic biomarker and tumor suppressor, is associated with immune cell infiltration in breast cancer: A bioinformatics analysis combined with experimental verification. <i>Cellular Signalling</i> , 2023, 112, 110918.	3.6	0
860	Machine Learning Developed a Programmed Cell Death Signature for Predicting Prognosis, Ecosystem, and Drug Sensitivity in Ovarian Cancer. <i>Analytical Cellular Pathology</i> , 2023, 2023, 1-21.	1.4	0
861	Pan-Cancer Analysis of the Prognostic and Immunological Role of $\beta$ SMG5: A Biomarker for Cancers. <i>Oncology</i> , 2024, 102, 168-182.	1.9	0
862	Adoption and use of immunotherapy in breast cancer management in Africa; barriers and prospect- a narrative review. <i>Annals of Medicine and Surgery</i> , 0, , .	1.1	0
863	Cancer-derived non-coding $\beta$ RNAs endow tumor microenvironment with immunosuppressive properties. <i>Wiley Interdisciplinary Reviews RNA</i> , 2024, 15, .	6.4	2
864	Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity. <i>Hepatology International</i> , 0, , .	4.2	0
865	Advancing Cancer Treatment Through Nanotechnology Driven Immunotherapy for Pancreatic Cancer. <i>ACS Applied Nano Materials</i> , 0, , .	5.0	0
866	Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: a comparative study of antitumor activity. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	0
867	Investigation of LGALS2 expression in the TCGA database reveals its clinical relevance in breast cancer immunotherapy and drug resistance. <i>Scientific Reports</i> , 2023, 13, .	3.3	0
870	Advancement of $\beta$ anti- $\beta$ LAG $\beta$ in cancer therapy. <i>FASEB Journal</i> , 2023, 37, .	0.5	4
871	Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer. <i>Aging</i> , 0, , .	3.1	1
872	New Insights into Immune Cells and Immunotherapy for Thyroid Cancer. <i>Immunological Investigations</i> , 2023, 52, 1039-1064.	2.0	1
873	Inflammation-related signature for prognostic prediction, tumor immune, genomic heterogeneity, and drug choices in prostate cancer: Integrated analysis of bulk and single-cell RNA-sequencing. <i>Heliyon</i> , 2023, 9, e21174.	3.2	0
874	Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities. <i>Molecules and Cells</i> , 2023, 46, 579-588.	2.6	1

#	ARTICLE	IF	CITATIONS
875	PIK3CD correlates with prognosis, epithelialâ€“mesenchymal transition and tumor immune infiltration in breast carcinoma. Discover Oncology, 2023, 14, .	2.1	0
876	Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2023, , 109225.	9.0	0
877	Single cell RNA sequencingâ€“ a valuable tool for cancer immunotherapy: a mini review. Oncologie, 2023, .	0.7	0
878	Application of exosomes as nanocarriers in cancer therapy. Journal of Materials Chemistry B, 0, , .	5.8	1
879	ZDHH9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance. Discover Oncology, 2023, 14, .	2.1	0
880	Implications of Rectal Cancer Radiotherapy on the Immune Microenvironment: Allies and Foes to Therapy Resistance and Patientsâ€™ Outcome. Cancers, 2023, 15, 5124.	3.7	0
881	The safety and anti-tumor effect of multiple peptides-pulsed dendritic cells combined with induced specific cytotoxic T lymphocytes for patients with solid tumors. Frontiers in Immunology, 0, 14, .	4.8	0
882	Advances in Immunomodulatory MOFs for Biomedical Applications. Small, 0, , .	10.0	3
883	Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	1
884	Construction and validation of a novel prognostic model of neutrophilâ€“related genes signature of lung adenocarcinoma. Scientific Reports, 2023, 13, .	3.3	1
885	Precision Nutrition and Cancer. , 2024, , 277-298.		1
886	Purine metabolism-related genes and immunization in thyroid eye disease were validated using bioinformatics and machine learning. Scientific Reports, 2023, 13, .	3.3	2
887	Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy. Cell Death and Disease, 2023, 14, .	6.3	0
888	Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer. Journal of Translational Medicine, 2023, 21, .	4.4	0
889	Peptide-nanoparticle conjugates as a theranostic platform. Coordination Chemistry Reviews, 2024, 500, 215530.	18.8	0
890	Engineered Extracellular Vesicles Expressing Siglecâ€“10 Camouflaged AIE Photosensitizer to Reprogram Macrophages to Active M1 Phenotype and Present Tumorâ€“Associated Antigens for Photodynamic Immunotherapy. Small, 0, , .	10.0	0
891	Emerging optogenetics technologies in biomedical applications. , 2023, 2, .		0
892	Self-reinforced photodynamic immunostimulator to downregulate and block PD-L1 for metastatic breast cancer treatment. Biomaterials, 2023, 303, 122392.	11.4	2



#	ARTICLE	IF	CITATIONS
893	Construction of disulfidptosis-related lncRNA signature for predicting the prognosis and immune escape in colon adenocarcinoma. BMC Gastroenterology, 2023, 23, .	2.0	1
894	Simultaneous selection of nanobodies for accessible epitopes on immune cells in the tumor microenvironment. Nature Communications, 2023, 14, .	12.8	0
895	Survival benefit and biomarker of PDâ€¹ inhibitor combination therapy in firstâ€¹line of advanced biliary tract cancer: A retrospective study. Cancer Medicine, 2023, 12, 20699-20711.	2.8	0
896	Identification of a bile acid and bile salt metabolism-related lncRNA signature for predicting prognosis and treatment response in hepatocellular carcinoma. Scientific Reports, 2023, 13, .	3.3	2
897	A Vaccine against Cancer: Can There Be a Possible Strategy to Face the Challenge? Possible Targets and Paradoxical Effects. Vaccines, 2023, 11, 1701.	4.4	1
898	Bacterial Flagellumâ€¹Drug Nanoconjugates for Carrierâ€¹Free Immunochemotherapy. Small, 0, , .	10.0	0
899	Neutrophil heterogeneity and aging: implications for COVID-19 and wound healing. Frontiers in Immunology, 0, 14, .	4.8	0
900	Direct visualization of immune status for tumorâ€¹infiltrating lymphocytes by rolling circle amplification. Journal of Biophotonics, 2024, 17, .	2.3	0
901	Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer. , 2023, 11, e007669.		0
902	Exploiting innate immunity for cancer immunotherapy. Molecular Cancer, 2023, 22, .	19.2	6
903	Peripheral macrophages in the development and progression of structural cerebrovascular pathologies. Journal of Cerebral Blood Flow and Metabolism, 2024, 44, 169-191.	4.3	0
904	Organic fluorophore-based fluorescent probes for abnormal immune response diagnosis and treatment evaluation. Sensors & Diagnostics, 0, , .	3.8	0
905	Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system. Frontiers in Immunology, 0, 14, .	4.8	1
906	IFN-Î³ lowers tumor growth by increasing glycolysis and lactate production in a nitric oxide-dependent manner: implications for cancer immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	0
907	The DCâ€¹T cell axis is an effective target for the treatment of nonâ€¹small cell lung cancer. Immunity, Inflammation and Disease, 2023, 11, .	2.7	0
908	Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	1
909	Multistage Self-Assembled Nanomaterials for Cancer Immunotherapy. Molecules, 2023, 28, 7750.	3.8	2
910	Cell membrane-based biomimetic technology for cancer phototherapy: Mechanisms, recent advances and perspectives. Acta Biomaterialia, 2024, 174, 26-48.	8.3	1

#	ARTICLE	IF	CITATIONS
911	Advances in tumor immunomodulation based on nanodrug delivery systems. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
912	NON-CYCLIC DINUCLEOTIDE STING AGONISTS FOR IMMUNO-ONCOLOGY. <i>Medicinal Chemistry Reviews</i> , 0, , 503-524.	0.1	0
913	A Prediction Model for Deciphering Intratumoral Heterogeneity Derived from the Microglia/Macrophages of Glioma Using Non-Invasive Radiogenomics. <i>Brain Sciences</i> , 2023, 13, 1667.	2.3	0
914	Global cluster analysis and network visualization in cancer-associated fibroblast: insights from Web of Science database from 1999 to 2021. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	0
915	Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2024, 75, 1-11.	7.2	0
916	A Systematic Immune and Prognostic Analysis of CD48 Interaction with Tumor Microenvironment in Pan-Cancer. <i>International Journal of General Medicine</i> , 0, Volume 16, 5255-5269.	1.8	0
917	PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
918	Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy. <i>Journal of Neuro-Oncology</i> , 0, , .	2.9	0
919	Improved survival for stage IV sinonasal small cell neuroendocrine carcinoma treated with chemotherapy and anti-PD-L1 therapy. <i>BMJ Case Reports</i> , 2023, 16, e255313.	0.5	0
920	Genomic Data Machined: The Random Forest Algorithm for Discovering Breast Cancer Biomarkers. <i>Lecture Notes in Networks and Systems</i> , 2023, , 428-443.	0.7	0
921	A Case of Success With Immunotherapy After Changing the Therapeutics Strategy in Non-small Cell Lung Cancer. <i>Cureus</i> , 2023, , .	0.5	0
923	Artificial Intelligence Applications for Biomedical Cancer Research: A Review. <i>Cureus</i> , 2023, , .	0.5	0
924	Manganese-Enriched Zinc Peroxide Functional Nanoparticles for Potentiating Cancer Immunotherapy. <i>Nano Letters</i> , 2023, 23, 10350-10359.	9.1	1
925	Retinoid X Receptor agonists as selective modulators of the immune system for the treatment of cancer. , 2023, 252, 108561.		0
926	Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells. <i>Journal of Leukocyte Biology</i> , 0, , .	3.3	0
927	Tumour suppressor ABCA8 inhibits malignant progression of colorectal cancer via Wnt/ $\beta^2$ -catenin pathway. <i>Digestive and Liver Disease</i> , 2023, , .	0.9	1
929	Doublet Therapy: Two Narrative Accounts of One Life-Changing Decision. <i>JCO Oncology Practice</i> , 2024, 20, 15-18.	2.9	1
930	Recognition and combination of multiple cell-death features showed good predictive value in lung adenocarcinoma. <i>Heliyon</i> , 2023, 9, e22434.	3.2	0

#	ARTICLE	IF	CITATIONS
931	Current progress of immune checkpoint inhibitors for advanced colorectal cancer: concentrating on the efficacy improvement. <i>Critical Reviews in Oncology/Hematology</i> , 2023, , 104204.	4.4	0
933	Editorial: Community series in the role of angiogenesis and immune response in tumor microenvironment of solid tumor: volume II. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
934	Antitumor effect of tubeimoside-I on murine colorectal cancers through PKM2-dependent pyroptosis and immunomodulation. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	3.0	0
935	CD80-fc fusion protein as a potential cancer immunotherapy strategy. <i>Antibody Therapeutics</i> , 0, , .	1.9	0
936	Unexpected Transient Glioblastoma Regression in a Patient Previously Treated with Bacillus Calmetteâ€“GuÃ©rin Therapy: A Case Report and Immunomodulatory Effects Hypothesis. <i>Journal of Personalized Medicine</i> , 2023, 13, 1661.	2.5	0
937	Identifying prognostic characteristics of m6A-related glycolysis gene and predicting the immune infiltration landscape in bladder cancer. <i>Cancer Cell International</i> , 2023, 23, .	4.1	0
938	Regulation of Antigenâ€“Specific Immunotherapy with Nanomaterials. <i>Advanced NanoBiomed Research</i> , 2023, 3, .	3.6	0
939	Transcriptionally activates CCL28 expression to inhibit M2 polarization of macrophages and prevent immune escape in colorectal cancer cells. <i>Translational Oncology</i> , 2024, 40, 101842.	3.7	0
940	Single-cell analysis unveils activation of mast cells in colorectal cancer microenvironment. <i>Cell and Bioscience</i> , 2023, 13, .	4.8	1
941	NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment. <i>Cells</i> , 2023, 12, 2748.	4.1	0
942	Protein cage nanoparticle-based NK cell-engaging nanodrones (NKeNDs) effectively recruit NK cells to target tumor sites and suppress tumor growth. <i>Nano Today</i> , 2024, 54, 102075.	11.9	0
943	Hydrogel-mediated tumor T cell infiltration and immune evasion to reinforce cancer immunotherapy. <i>Nanoscale Horizons</i> , 0, , .	8.0	0
944	Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts. <i>International Immunopharmacology</i> , 2024, 126, 111281.	3.8	1
945	The application of nanoparticles based on ferroptosis in cancer therapy. <i>Journal of Materials Chemistry B</i> , 0, , .	5.8	0
946	Receptor tyrosine kinases: biological functions and anticancer targeted therapy. <i>MedComm</i> , 2023, 4, .	7.2	0
948	Microwave-responsive gadolinium metal-organic frameworks nanosystem for MRI-guided cancer thermotherapy and synergistic immunotherapy. <i>Bioactive Materials</i> , 2024, 33, 532-544.	15.6	0
949	Beyond the horizon: Neutrophils leading the way in the evolution of immunotherapy. <i>Cancer Medicine</i> , 0, , .	2.8	0
950	Engineering Probiotic E. coli Nissle 1917 for Release of Therapeutic Nanobodies. <i>Methods in Molecular Biology</i> , 2024, , 289-305.	0.9	0

#	ARTICLE	IF	CITATIONS
953	Microbiota: A key factor affecting and regulating the efficacy of immunotherapy. Clinical and Translational Medicine, 2023, 13, .	4.0	1
954	Advances in Targeted Immunotherapy in Cancers. International Journal of Molecular Sciences, 2023, 24, 17475.	4.1	0
955	The Role of Tumor Metabolic Reprogramming in Tumor Immunity. International Journal of Molecular Sciences, 2023, 24, 17422.	4.1	1
956	Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia. , 2024, 41, .		0
957	Multifunctional Probe Based on “Chemical Antibody” Aptamer for Noninvasive Detection of PD-L1 Expression in Cancer. Molecular Pharmaceutics, 0, , .	4.6	0
958	Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	6
959	Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma. Cancer Biotherapy and Radiopharmaceuticals, 0, , .	1.0	1
960	Construction of a prognostic model for lung adenocarcinoma based on m6A/m5C/m1A genes. Human Molecular Genetics, 0, , .	2.9	0
961	A Bimetallic Polymerization Network for Effective Increase in Labile Iron Pool and Robust Activation of cGAS/STING Induces Ferroptosis-Based Tumor Immunotherapy. Small, 0, , .	10.0	0
962	Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study. Cancer Chemotherapy and Pharmacology, 0, , .	2.3	0
963	A comprehensive analysis of the expression, immune infiltration, prognosis and partial experimental validation of CHST family genes in gastric cancer. Translational Oncology, 2024, 40, 101843.	3.7	0
964	Evidence of direct interaction between cisplatin and the caspase-cleaved prostate apoptosis response-4 tumor suppressor. Protein Science, 2024, 33, .	7.6	0
965	Computational simulations of bispecific T cell engagers by a multiscale model. Biophysical Journal, 2023, , .	0.5	0
967	Construction and validation of a prognostic signature based on seven endoplasmic reticulum stress-related lncRNAs for patients with head and neck squamous cell carcinoma. Scientific Reports, 2023, 13, .	3.3	0
968	Novel Pt(IV) complex OAP2 induces STING activation and pyroptosis via mitochondrial membrane remodeling for synergistic chemo-immunotherapy. Acta Pharmaceutica Sinica B, 2024, 14, 1742-1758.	12.0	0
969	Nanocodelivery of an NIR photothermal agent and an acid-responsive TLR7 agonist prodrug to enhance cancer photothermal immunotherapy and the abscopal effect. Biomaterials, 2024, 305, 122434.	11.4	0
970	Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond. Biomolecules, 2023, 13, 1803.	4.0	1
971	SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy. International Immunopharmacology, 2024, 127, 111376.	3.8	0

#	ARTICLE	IF	CITATIONS
972	Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, M1t, and DC-Based Treatments. International Journal of Molecular Sciences, 2023, 24, 17634.	4.1	2
974	Characterization of tumor-associated endothelial cells and the development of a prognostic model in pancreatic ductal adenocarcinoma. Biochimica Et Biophysica Acta - General Subjects, 2024, 1868, 130545.	2.4	0
975	Role of Tumor Budding and fibrotic cancer stroma in Head and Neck Squamous Cell Carcinoma. Pathology Research and Practice, 2023, , 155052.	2.3	0
976	Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer. Aging, 2023, 15, 15134-15160.	3.1	1
977	Advances in Rolling Circle Amplification (RCA)â€Based DNAâ€Functional Materials for Cancer Diagnosis and Therapy. Advanced NanoBiomed Research, 2024, 4, .	3.6	0
979	Panâ€cancer analysis identifies the IRF family as a biomarker for survival prognosis and immunotherapy. Journal of Cellular and Molecular Medicine, 2024, 28, .	3.6	0
980	An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?. Expert Review of Neurotherapeutics, 2024, 24, 77-103.	2.8	0
981	The role of intestinal flora on tumor immunotherapy: recent progress and treatment implications. Heliyon, 2024, 10, e23919.	3.2	0
983	Antitumor Immunity: Role of NK Cells and Extracellular Vesicles in Cancer Immunotherapy. Current Issues in Molecular Biology, 2024, 46, 140-152.	2.4	0
984	Intravenous Senescent Erythrocyte Vaccination Modulates Adaptive Immunity and Splenic Complement Production. ACS Nano, 0, , .	14.6	0
985	Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy. Archives of Medical Research, 2024, 55, 102927.	3.3	0
986	A novel oxidative stress-related gene signature as an indicator of prognosis and immunotherapy responses in HNSCC. Aging, 0, , .	3.1	0
987	Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2024, 1879, 189066.	7.4	0
988	Decoding cancer insights: recent progress and strategies in proteomics for biomarker discovery. Journal of Proteins and Proteomics, 2024, 15, 67-87.	1.5	0
989	Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies. , 2024, 3, .		1
990	Withanolides: Promising candidates for cancer therapy. Phytotherapy Research, 2024, 38, 1104-1158.	5.8	0
991	Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment. Biomaterials, 2024, 305, 122463.	11.4	2
992	Evaluating the impact of PD-1 inhibitor treatment on key health outcomes for cancer patients in China. International Journal of Clinical Pharmacy, 2024, 46, 429-438.	2.1	0

#	ARTICLE	IF	CITATIONS
993	Integrative analysis of single-cell and bulk RNA-sequencing data revealed T cell marker genes based molecular sub-types and a prognostic signature in lung adenocarcinoma. Scientific Reports, 2024, 14, .	3.3	0
994	Therapeutic and diagnostic applications of carbon nanotubes in cancer: recent advances and challenges. Journal of Drug Targeting, 2024, 32, 287-299.	4.4	1
995	Recent advances in the metal/organic hybrid nanomaterials for cancer theranostics. Coordination Chemistry Reviews, 2024, 504, 215654.	18.8	0
996	Calreticulin, a potential coregulator of immune checkpoints and biomarker associated with tumor microenvironment and clinical prognostic significance in breast invasive carcinoma. Environmental Toxicology, 2024, 39, 2717-2731.	4.0	0
997	Integration of multi-omics and clinical treatment data reveals bladder cancer therapeutic vulnerability gene combinations and prognostic risks. Frontiers in Immunology, 0, 14, .	4.8	1
998	The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy. Frontiers in Immunology, 0, 15, .	4.8	0
999	Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy. European Journal of Medical Research, 2024, 29, .	2.2	0
1000	Research progress of exosomes in drug resistance of breast cancer. Frontiers in Bioengineering and Biotechnology, 0, 11, .	4.1	0
1001	The potential value of the Purinergic pathway in the prognostic assessment and clinical application of kidney renal clear cell carcinoma. Aging, 0, , .	3.1	0
1002	Integrated bioinformatics analysis and experimental validation identified CDCA families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma. PLoS ONE, 2024, 19, e0295346.	2.5	0
1003	SNRPB promotes the progression of hepatocellular carcinoma via regulating cell cycle, oxidative stress, and ferroptosis. Aging, 0, , .	3.1	0
1004	The development and technologies of RNA therapeutics. Progress in Molecular Biology and Translational Science, 2024, , 13-39.	1.7	0
1005	Identifying the prognosis implication, immunotherapy response prediction value, and potential targeted compound inhibitors of integrin subunit $\alpha 3$ (ITGA3) in human cancers. Heliyon, 2024, 10, e24236.	3.2	0
1006	TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study. Therapeutic Advances in Medical Oncology, 2024, 16, .	3.2	0
1007	A new target of radiotherapy combined with immunotherapy: regulatory T cells. Frontiers in Immunology, 0, 14, .	4.8	0
1008	G6PD is a prognostic biomarker correlated with immune infiltrates in lung adenocarcinoma and pulmonary arterial hypertension. Aging, 0, , .	3.1	0
1011	Immune landscape and heterogeneity of cervical squamous cell carcinoma and adenocarcinoma. Aging, 0, , .	3.1	0
1012	Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity. Heliyon, 2024, 10, e24454.	3.2	0

#	ARTICLE	IF	CITATIONS
1014	Engineering mesoporous bioactive glasses for emerging stimuli-responsive drug delivery and theranostic applications. <i>Bioactive Materials</i> , 2024, 34, 436-462.	15.6	0
1015	Disulfidptosis-related classification patterns and tumor microenvironment characterization in skin cutaneous melanoma. <i>Melanoma Management</i> , 2023, 10, .	0.5	0
1016	Association Between Diverse Cell Death Patterns Related Gene Signature and Prognosis, Drug Sensitivity, and Immune Microenvironment in Glioblastoma. <i>Journal of Molecular Neuroscience</i> , 2024, 74, .	2.3	0
1017	Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of solid tumors. <i>The Cochrane Library</i> , 2024, 2024, .	2.8	0
1018	Glutamine metabolism-related genes and immunotherapy in nonspecific orbital inflammation were validated using bioinformatics and machine learning. <i>BMC Genomics</i> , 2024, 25, .	2.8	0
1019	Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer. <i>Acta Biomaterialia</i> , 2024, 176, 344-355.	8.3	1
1020	A Machine Learning Approach for Predicting Microsatellite Instability using RNA-seq. , 2023, , .		0
1021	Gasdermins: a dual role in pyroptosis and tumor immunity. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
1022	Imaging of Extravasation of Splenocytes in the Dorsal Skinfold Window Chamber. <i>Methods in Molecular Biology</i> , 2024, , 137-155.	0.9	0
1023	Pan-cancer analysis of HAVCR2 based on machine learning: A potential target of survival and immunotherapy. , 2023, , .		0
1025	Interplay between posttranslational modifications and liquidâ€™liquid phase separation in tumors. <i>Cancer Letters</i> , 2024, 584, 216614.	7.2	1
1026	Proteome-wide Mendelian randomization identifies causal plasma proteins in lung cancer. <i>IScience</i> , 2024, 27, 108985.	4.1	0
1027	The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer. <i>European Journal of Clinical Pharmacology</i> , 2024, 80, 519-527.	1.9	0
1028	Erzhi pills reverse PD-L1-mediated immunosuppression in melanoma microenvironment. <i>Heliyon</i> , 2024, 10, e24988.	3.2	0
1029	Metformin improved a heterologous prime-boost of dual-targeting cancer vaccines to inhibit tumor growth in a melanoma mouse model. <i>International Immunopharmacology</i> , 2024, 128, 111431.	3.8	0
1030	Identification of BANF1 as a novel prognostic biomarker in gastric cancer and validation via in-vitro and in-vivo experiments. <i>Aging</i> , 2024, 16, 1808-1828.	3.1	0
1031	UCLH-3 as a potential biomarker of ovarian cancer. <i>Gynecologic Oncology</i> , 2024, 182, 156-167.	1.4	0
1032	Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma. <i>Functional and Integrative Genomics</i> , 2024, 24, .	3.5	0



#	ARTICLE	IF	CITATIONS
1033	Machine learning identifies SLC6A14 as a novel biomarker promoting the proliferation and metastasis of pancreatic cancer via Wnt/ $\beta$ 2-catenin signaling. Scientific Reports, 2024, 14, .	3.3	0
1034	ATP-adenosine axis regulation combined with microneedle assisted photoimmunotherapy to boost the immunotherapy efficiency. Journal of Controlled Release, 2024, 367, 1-12.	9.9	0
1035	Ribosome profiling: a powerful tool in oncological research. Biomarker Research, 2024, 12, .	6.8	0
1036	Tumor-derived KLK8 predicts inferior survival and promotes an immune-suppressive tumor microenvironment in lung squamous cell carcinoma. BMC Pulmonary Medicine, 2024, 24, .	2.0	0
1037	Patient-derived organoids: a promising tool for breast cancer research. Frontiers in Oncology, 0, 14, .	2.8	0
1038	Mononuclear phagocyte system-related multi-omics features yield head and neck squamous cell carcinoma subtypes with distinct overall survival, drug, and immunotherapy responses. Journal of Cancer Research and Clinical Oncology, 2024, 150, .	2.5	0
1039	Pyroptosis in cancer treatment and prevention: the role of natural products and their bioactive compounds. , 2024, 41, .		0
1040	Cancer metabolism and carcinogenesis. Experimental Hematology and Oncology, 2024, 13, .	5.0	0
1041	Unlocking the "ova"™-coming power: immunotherapy's role in shaping the future of ovarian cancer treatment. , 2024, 41, .		0
1042	Stimuli-Responsive Polymeric Nanomedicine for Enhanced Cancer Immunotherapy. Chemistry of Materials, 2024, 36, 1088-1112.	6.7	0
1044	Social and Biological Determinants in Lung Cancer Disparity. Cancers, 2024, 16, 612.	3.7	0
1045	Roles of exosomes in immunotherapy for solid cancers. Cell Death and Disease, 2024, 15, .	6.3	0
1046	Downregulation of dermatopontin in cholangiocarcinoma cells suppresses CCL19 secretion of macrophages and immune infiltration. Journal of Cancer Research and Clinical Oncology, 2024, 150, .	2.5	0
1047	T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution. Journal of Experimental and Clinical Cancer Research, 2024, 43, .	8.6	1
1048	A new 4-gene-based prognostic model accurately predicts breast cancer prognosis and immunotherapy response by integrating WGCNA and bioinformatics analysis. Frontiers in Immunology, 0, 15, .	4.8	0
1049	Multifaceted roles and functions of SOX30 in human cancer. , 2024, 3, .		0
1050	Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors. Small, 0, , .	10.0	0
1052	Single-cell RNA sequencing reveals the MIF-ACKR3 receptor-ligand interaction between iCAFs and tumor cells in esophageal squamous cell carcinoma. Cellular Signalling, 2024, 117, 111093.	3.6	0

#	ARTICLE	IF	CITATIONS
1053	Molecular mechanism of specific HLA-A mRNA recognition by the RNA-binding-protein hMEX3B to promote tumor immune escape. <i>Communications Biology</i> , 2024, 7, .	4.4	0
1054	Non-coding RNAs as therapeutic targets in cancer and its clinical application. <i>Journal of Pharmaceutical Analysis</i> , 2024, , .	5.3	0
1055	Immune checkpoint ligands expressed on mature high endothelial venules predict poor prognosis of NSCLC: have a relationship with CD8+ T lymphocytes infiltration. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
1056	The role of intratumoral microorganisms in the progression and immunotherapeutic efficacy of head and neck cancer. <i>Oncologie</i> , 2024, .	0.7	0
1057	Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody. <i>European Journal of Medicinal Chemistry</i> , 2024, 267, 116206.	5.5	0
1058	A comprehensively prognostic and immunological analysis of PARP11 in pan-cancer. <i>Journal of Leukocyte Biology</i> , 0, , .	3.3	0
1059	An Analysis Regarding the Association Between DAZ Interacting Zinc Finger Protein 1 (DZIP1) and Colorectal Cancer (CRC). <i>Molecular Biotechnology</i> , 0, , .	2.4	0
1060	Peptide-Functionalized Inorganic Oxide Nanomaterials for Solid Cancer Imaging and Therapy. <i>Advanced Materials</i> , 0, , .	21.0	0
1061	Redox-regulating nanotherapeutics potentiating ferroptosis-driven cancer treatment. <i>Chemical Engineering Journal</i> , 2024, 484, 149518.	12.7	0
1062	Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
1063	Theranostic Uses of the Heme Pathway in Neuro-Oncology: Protoporphyrin IX (PpIX) and Its Journey from Photodynamic Therapy (PDT) through Photodynamic Diagnosis (PDD) to Sonodynamic Therapy (SDT). <i>Cancers</i> , 2024, 16, 740.	3.7	0
1065	Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. <i>Molecular and Cellular Proteomics</i> , 2024, 23, 100737.	3.8	0
1068	Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises. <i>Cells</i> , 2024, 13, 337.	4.1	0
1069	Comprehensive analysis of disulfidptosis-related genes: a prognosis model construction and tumor microenvironment characterization in clear cell renal cell carcinoma. <i>Aging</i> , 2024, 16, 3647-3673.	3.1	0
1070	Styryl carbamate backbones for the discovery of TME-disrupting agents. <i>Results in Chemistry</i> , 2024, 7, 101372.	2.0	0
1071	The trends and hotspots of immunotherapy for metastatic colorectal cancer from 2013 to 2022: A bibliometric and visual analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 20, .	3.3	0
1072	The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management. <i>Cancers</i> , 2024, 16, 795.	3.7	0
1073	Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering. <i>Journal of Chemical Information and Modeling</i> , 2024, 64, 1615-1627.	5.4	0

#	ARTICLE	IF	CITATION
1074	Engineered Tumorâ€‘Immune Microenvironment On A Chip to Study T Cellâ€‘Macrophage Interaction in Breast Cancer Progression. Advanced Healthcare Materials, 0, , .	7.6	0
1075	Engineered Bioâ€‘Based Hydrogels for Cancer Immunotherapy. Advanced Materials, 0, , .	21.0	0
1076	Long noncoding RNA LINC00921 serves as a predictive biomarker for lung adenocarcinoma: An observational study. Medicine (United States), 2024, 103, e37179.	1.0	0
1077	From pain to tumor immunity: influence of peripheral sensory neurons in cancer. Frontiers in Immunology, 0, 15, .	4.8	0
1078	Metalâ€‘Organic Frameworkâ€‘Based Nanomaterials for Regulation of the Osteogenic Microenvironment. Small, 0, , .	10.0	0
1079	Machine learning-based investigation of regulated cell death for predicting prognosis and immunotherapy response in glioma patients. Scientific Reports, 2024, 14, .	3.3	0
1080	HERVK-mediated regulation of neighboring genes: implications for breast cancer prognosis. Retrovirology, 2024, 21, .	2.0	0
1081	PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy. , 2024, 3, 100146.		0
1082	<scp>STING</scp> activator 2â€‘3â€‘2â€‘<scp>cGAMP</scp> enhanced <scp>HSV</scp>-based oncolytic viral therapy. Molecular Oncology, 0, , .	4.6	0
1083	Molecular classification and tumor microenvironment characteristics in pheochromocytomas. ELife, 0, 12, .	6.0	0
1084	KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC. Cell Death and Disease, 2024, 15, .	6.3	0
1085	Seizing the fate of lymph nodes in immunotherapy: To preserve or not?. Cancer Letters, 2024, 588, 216740.	7.2	0
1086	KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST. Cell Communication and Signaling, 2024, 22, .	6.5	0
1087	Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections. Respiratory Investigation, 2024, 62, 339-347.	1.8	0
1088	Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy. Molecular and Cellular Biochemistry, 0, , .	3.1	0
1089	Recent advances in NO-triggered gas therapy by metal-organic frameworks. Materials Today Chemistry, 2024, 36, 101964.	3.5	0
1090	Pan-cancer analysis reveals potential immunological and prognostic roles of COA6 in human cancers and preliminary exploration of COA6 in bladder cancer. Cellular Signalling, 2024, 117, 111111.	3.6	0
1091	Targets of tumor microenvironment for potential drug development. , 2024, 3, .		0

#	ARTICLE	IF	CITATIONS
1092	The prognostic value of LAYN in HPV-related head and neck squamous cell carcinoma and its influence on immune cell infiltration. Discover Oncology, 2024, 15, .	2.1	0
1093	Black phosphorus-based nanoparticles induce liver cancer cell mitochondrial apoptosis and immune cell tumor infiltration for enhancing dendritic cell therapy. Heliyon, 2024, 10, e27234.	3.2	0
1094	A Risk Score Based on Immune- and Oxidative Stress-Related LncRNAs Predicts Prognosis in Lung Adenocarcinoma: Insights from in vitro Experiments and Large-Scale Transcriptome Analysis. Journal of Inflammation Research, 0, Volume 17, 1453-1465.	3.5	0
1096	Immunotherapy in Oncology: A Comprehensive Overview from a Pathological Perspective. , 2024, , .		0
1097	Single-cell RNA combined with Bulk RNA analysis to explore oxidative stress and energy metabolism factors and found a new prostatic cancer oncogene MXRA8. Aging, 0, , .	3.1	0
1098	Pancancer analysis of the prognostic and immunological role of FANCD2: a potential target for carcinogenesis and survival. BMC Medical Genomics, 2024, 17, .	1.5	0
1099	Research progress in cell therapy for oral diseases: focus on cell sources and strategies to optimize cell function. Frontiers in Bioengineering and Biotechnology, 0, 12, .	4.1	0
1100	Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade. Journal of Oral Pathology and Medicine, 2024, 53, 217-225.	2.7	0
1101	Unlocking potential biomarkers bridging coronary atherosclerosis and pyrimidine metabolism-associated genes through an integrated bioinformatics and machine learning approach. BMC Cardiovascular Disorders, 2024, 24, .	1.7	0
1102	Cuprous oxide nanocomposites with photothermal (PTT) and chemical dynamics (CDT) effects induce cuproptosis in breast cancer using the strategy of increasing inflow and reducing outflow. Nano Today, 2024, 56, 102223.	11.9	0
1103	Screening of genes characteristic of pancreatic cancer by LASSO regression combined with support vector machine and recursive feature elimination, and immune correlation analysis. Journal of International Medical Research, 2024, 52, .	1.0	0
1104	The recent advancement of TCR-T cell therapies for cancer treatment. Acta Biochimica Et Biophysica Sinica, 2024, , .	2.0	0
1105	Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. , 2024, 12, e007364.		0
1106	Barriers And Challenges Of Multidisciplinary Teams In Oncology Management: A Scoping Review Protocol. BMJ Open, 2024, 14, e079559.	1.9	0
1108	Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review. Cureus, 2024, , .	0.5	0
1109	Identification of prognostic models for glycosylation-related subtypes and tumor microenvironment infiltration characteristics in clear cell renal cell cancer. Heliyon, 2024, 10, e27710.	3.2	0
1110	Immune-mediated hepatitis: Basic concepts and treatment. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2024, 89, 106-120.	0.2	0
1111	Role of Helicobacter pylori virulence factors and alteration of the Tumor Immune Microenvironment: challenges and opportunities for Cancer Immunotherapy. Archives of Microbiology, 2024, 206, .	2.2	0

#	ARTICLE	IF	CITATIONS
1112	Pan-cancer identified ARPC1B as a promising target for tumor immunotherapy and prognostic biomarker, particularly in READ. Heliyon, 2024, 10, e28005.	3.2	0
1114	Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. Drug Resistance Updates, 2024, 74, 101080.	14.4	0
1115	Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020â€“2023). Expert Opinion on Therapeutic Patents, 2024, 34, 83-98.	5.0	0
1116	Metalâ€based smart nanosystems in cancer immunotherapy. Exploration, 0, , .	11.0	0
1117	Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming. Cancer Letters, 2024, 589, 216824.	7.2	0
1118	Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy. Acta Pharmaceutica Sinica B, 2024, , .	12.0	0
1119	Pan-cancer and single-cell analyses identify CD44 as an immunotherapy response predictor and regulating macrophage polarization and tumor progression in colorectal cancer. Frontiers in Oncology, 0, 14, .	2.8	0
1120	Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients. BMC Cancer, 2024, 24, .	2.6	0
1121	Machine learning developed a CD8+ exhausted T cells signature for predicting prognosis, immune infiltration and drug sensitivity in ovarian cancer. Scientific Reports, 2024, 14, .	3.3	0
1122	COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma. Aging, 2024, 16, 5264-5287.	3.1	0
1123	Engineering immune response to regulate cardiovascular disease and cancer. Advances in Protein Chemistry and Structural Biology, 2024, , .	2.3	0
1124	Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas. Frontiers in Immunology, 0, 15, .	4.8	0
1125	Magnetic natural lipid nanoparticles for oral treatment of colorectal cancer through potentiated antitumor immunity and microbiota metabolite regulation. Biomaterials, 2024, 307, 122530.	11.4	0
1126	Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma. Frontiers in Oncology, 0, 14, .	2.8	0
1127	Computational analysis of PD-L1 dimerization mechanism induced by small molecules and potential dynamical properties. International Journal of Biological Macromolecules, 2024, 265, 130921.	7.5	0
1128	Targeting EGFR and VEGFR-2 Kinases With Nanoparticles: A Computational Approach for Cancer Therapy Advancement. Cancer Investigation, 2024, 42, 176-185.	1.3	0
1129	Mapping the intellectual structure and landscape of colorectal cancer immunotherapy: A bibliometric analysis. Human Vaccines and Immunotherapeutics, 2024, 20, .	3.3	0
1130	Bidirectional crosstalk between the epithelial-mesenchymal transition and immunotherapy: A bibliometric study. Human Vaccines and Immunotherapeutics, 2024, 20, .	3.3	0

#	ARTICLE	IF	CITATIONS
1131	Advancements in CAR-T cell engineering: paving the way for enhanced cancer immunotherapy. Frontiers in Immunology, 0, 15, .	4.8	0
1132	Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors. Bioactive Materials, 2024, 36, 376-412.	15.6	0
1133	Identification and Validation of T-Cell Exhaustion Signature for Predicting Prognosis and Immune Response in Pancreatic Cancer by Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data. Diagnostics, 2024, 14, 667.	2.6	0
1134	Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. Cancers, 2024, 16, 1237.	3.7	0
1136	Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model. Cancer Drug Resistance (Alhambra, Calif ), 0, , .	2.1	0